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ABSTRACT 
The prevalence of immune-mediated diseases is rising rapidly in our aging 
population. Currently used biomarkers are inaccurate and have a low predictive 
value, which complicates early diagnosis and evaluation of the efficacy of a given 
treatment. Consequently, there is an urgent need for novel biomarkers for immune-
mediated diseases at present. Proprotein convertase subtilisin/kexin (PCSK) 
enzymes have an important role in regulating general homeostasis by dictating the 
bioavailability of a variety of secretory and cell-surface proteins. The first found 
PCSK enzyme Furin is readily upregulated during immune cell activation. It regulates 
T cell functions and induces the processing of toll-like receptor 7 in innate immune 
cells to promote host defense against intracellular and extracellular pathogens. 
Furthermore, T-cell-expressed Furin favors T helper 1 cell polarization and 
promotes proper forkhead box P3+ T regulatory cell functions. Hence in addition 
to its key regulatory role in innate and adaptive immune responses, Furin is crucial 
for the maintenance of peripheral immunological tolerance. On the contrary, 
alterations in Furin expression have been associated with several immune-mediated 
diseases. 
This study investigated the role of Furin expression in acute infection, primary 
Sjögren’s syndrome and rheumatoid arthritis using various detection methods. The 
main aim was to assess how Furin levels correlate with clinical parameters in order 
to study its potential value as a biomarker for the aforementioned immune-mediated 
diseases. The results show that the Furin plasma level does not identify severe 
infections or initial pathogens in the early phase of infections. However, Furin 
expression was significantly elevated in both primary Sjögren’s syndrome and 
rheumatoid arthritis. Elevated Furin levels were associated with high interferon-γ 
levels and prolonged symptoms of dry eye in the group of patients with primary 
Sjögren’s syndrome. Patients with high Furin levels also showed a trend toward 
lower β2-microglobulin levels, erythrocyte sedimentation rate, and systemic disease 
activity index ESSDAI. In contrast, Furin plasma levels were not associated with 
clinical parameters in patients with rheumatoid arthritis. However, elevated Furin 
messenger ribonucleic acid levels were significantly associated with prednisolone use 
  
and prednisolone doses, C-reactive protein levels, and general disability index 
(Health Assessment Questionnaire). 
Collectively, this study shows that Furin plasma measurements do not have a 
predictive or diagnostic value in the early phase evaluation of patients with suspected 
infection. On the contrary, Furin was significantly upregulated in both primary 
Sjögren’s syndrome and rheumatoid arthritis, suggesting that it may have a role in 
the pathogenesis of autoimmune diseases. However, the observations of Furin 
effects turned out contradictory:  Results from the primary Sjögren’s syndrome 
group suggested its protective role in the disease development, whereas elevated 
levels in rheumatoid arthritis indicated a more severe and refractory disease. This 
discrepancy could be a result of its extensive substrate selection. Furin is known to 
activate both proinflammatory and anti-inflammatory factors, which could lead to 
its varying effects in terms of distinct pathophysiological mechanisms. Additional 
studies and novel methods for the detection of Furin are needed to further evaluate 
the clinical relevance of Furin expression in predicting immune-mediated diseases 
and understand its fundamental nature in health and disease.  
  
TIIVISTELMÄ 
Immuunivälitteiset sairaudet ovat yleistyvä ongelma väestön ikääntyessä. Tällä 
hetkellä käytössä olevat biomarkkerit ovat kuitenkin epätarkkoja ja ennustearvoltaan 
heikkoja, minkä vuoksi tämän potilasryhmän varhainen tunnistaminen ja tehokas 
hoito on osoittautunut haastavaksi. Proproteiinikonvertaasi subtilisiini/keksiini 
(PCSK) entsyymit kontrolloivat useiden, solujen tuottamien proteiinien 
bioaktiivisuutta ja ovat siten keskeisiä elimistön homeostasian säätelytekijöitä. Furin 
on eniten tutkittu PCSK-entsyymi ja sen ilmentyminen on todettu lisääntyvän 
erityisesti immuunijärjestelmän aktivaatiossa. Furin edistää toll-like reseptori 7:n 
prosessointia luonnollisen immuunivasteen soluissa sekä säätelee T-auttajasolujen 
toimintaa suosimalla TH1-tyyppistä immuunivastetta. Lisäksi sen ilmentyminen T-
auttajasoluissa voimistaa forkhead box P3 positiivisten T-säätelijäsolujen tulehdusta 
hillitsevää toimintaa ja rajoittaa siten liiallista tulehdusreaktiota. Furin on keskeinen 
tekijä sekä luonnollisen että hankitun immuunivasteen säätelyssä ja sen poikkeava 
ilmentyminen on yhdistetty immuunivasteen toiminnan häiriöihin sekä useisiin 
immuunivälitteisiin sairauksiin. Tästä huolimatta sen perimmäinen rooli 
immuunijärjestelmän toiminnassa tunnetaan edelleen puutteellisesti. Näin ollen 
tutkimuksia Furinin käyttömahdollisuuksista kliinisessä työssä on vasta vähän. 
Tässä väitöskirjassa tutkittiin Furinin ilmentymistä akuutissa infektiossa, 
primaarissa Sjögrenin syndroomassa ja nivelreumassa hyödyntäen erilaisia 
mittausmenetelmiä ja kliinisiä potilasaineistoja. Päätavoitteena oli selvittää Furin-
mittausten käytettävyyttä infektiotautien biomarkkerina päivystyspoliklinikalla sekä 
niiden kliinistä relevanssia edellä mainittujen autoimmuunisairauksien 
diagnostiikassa, hoidon suunnittelussa ja seurannassa. Tulosten perusteella Furinin 
plasmapitoisuus ei ennusta kuolleisuutta eikä tunnista bakteeritulehdusta 
infektiopotilaiden päivystyksellisen arvioinnin yhteydessä. Sen sijaan plasman Furin-
pitoisuudet olivat merkitsevästi korkeampia potilailla, joiden sairaushistoriasta löytyi 
diagnosoitu reumatauti.  Tutkimuksissamme Furinin ilmentyminen osoittautui 
selvästi kohonneeksi sekä primaarissa Sjögrenin syndroomassa että nivelreumassa. 
Primaarissa Sjögrenin syndroomassa korkea Furin-plasmapitoisuus oli yhteydessä 
korkeisiin interferoni-γ tasoihin sekä pidempikestoisiin kuivasilmäisyysoireisiin. 
Lisäksi havaittiin trendi, jossa lasko, systeeminen tautiaktiivisuusindeksi ESSDAI ja 
  
seerumin β2-mikroglobuliini olivat keskimäärin matalampia potilailla, joiden plasman 
Furin oli korkea.  Sen sijaan Furinin plasmapitoisuudet eivät liittyneet kliinisiin 
parametreihin nivelreumapotilaista koostuvassa aineistossa. Kuitenkin Furinia 
koodaavan lähetti-RNA:n lisääntynyt pitoisuus perifeerisen veren 
mononukleaarisissa soluissa liittyi merkitsevästi kortisonilääkityksen tarpeeseen ja 
kortisoniannokseen, koholla olevaan C-reaktiiviseen proteiiniin sekä 
toiminnanvajeeseen toimintakykykyselyssä (Health Assessment Questionnaire). 
Tämä väitöskirja osoitti, että Furin ei sovellu infektiomittariksi 
päivystyspoliklinikalla eikä sen plasmapitoisuudesta voida tehdä johtopäätöksiä 
liittyen taudin vaikeusasteeseen tai potilaan ennusteeseen. Lisäksi Furinin pitoisuutta 
plasmassa ei voida hyödyntää empiirisen antibiootin valinnassa taudin alkuvaiheessa. 
Toisaalta Furinin ilmentymisen todettiin lisääntyvän merkitsevästi sekä primaarissa 
Sjögrenin syndroomassa että nivelreumassa. Tulokset viittasivat Furinin 
mahdollisesti suojaavaan vaikutukseen primaarissa Sjögrenin syndroomassa, kun taas 
nivelreumassa korkea Furin-taso näytti liittyvän aktiivisempaan ja hoitoresistenttiin 
taudinkuvaan. Tutkimuksissa tehtyjen löydösten perusteella Furinin toiminta ja 
ilmentyminen saattaa olla merkityksellistä autoimmuunisairauksien patogeneesissä. 
Furin käyttäytyy mahdollisesti tautispesifisesti johtaen joko aktiivisempaan 
(nivelreuma) tai lievempään (primaari Sjögrenin syndrooma) taudinkuvaan riippuen 
taudin taustalla olevasta patogeneesistä. Tämä voisi selittyä Furinin laajalla 
substraattivalikoimalla. Koska Furin aktivoi sekä immuunivastetta hillitseviä että 
kiihdyttäviä tekijöitä, erilaiset patomekanismit voisivat vaikuttaa Furinin rooliin 
immuunijärjestelmän toiminnassa. Jatkotutkimukset ovat välttämättömiä Furinin 
toiminnan ymmärtämisessä sekä arvioitaessa sen kliinistä käytettävyyttä 
immuunivälitteisten sairauksien diagnostiikassa sekä hoidon seurannassa. Uudet 
mittausmetodit saattavat olla ratkaisevassa roolissa avaten uusia mahdollisuuksia 
hyödyntää Furinia kliinisessä päätöksenteossa. 
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MC mononuclear cell 
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1 INTRODUCTION 
The human immune system is a complex network that provides defense against 
infectious pathogens including viruses, bacteria, parasites and fungi. In addition, it 
disposes deregulated host cells and cell debris to maintain cellular homeostasis. The 
immune system is traditionally divided into two subsystems known as innate and 
adaptive immune systems. Innate immunity is characterized by fast and nonspecific 
acts against commonly encountered invaders, whereas adaptive immunity is able to 
supply relatively slow, but highly specific, effector functions and has long-lasting 
features. The immune system consists of primary and secondary lymphatic organs, 
initial barriers, immune cells, and a vast number of soluble immune mediators. 
Because of comprehensive cellular signaling, the aforementioned subsystems are 
able to complement each other and produce an effective host response against 
various internal and external threats. However, dysregulated host defense can be 
detrimental and lead to severe health problems, such as immunodeficiency, allergies, 
and autoimmunity. These are generally referred to as immune-mediated diseases 
(IMDs) and are characterized by tissue damage caused by incorrectly operating 
immune cells and cytokine dysregulation. 
IMDs are an increasing health concern in our aging population. It is estimated 
that rheumatoid arthritis (RA) alone affects around 1% of all adults, putting a 
significant economic burden on our society. In addition, the symptoms cause 
functional disability and result in a notable decrease in the measured quality of life. 
Despite intensive research work, the underlying factors in the lost control of immune 
response remain elusive. As a consequence, the development of effective diagnostic 
tools and targeted treatment methods has become a challenge. Combinations of 
symptoms, clinical signs, laboratory tests, imaging and biopsies are currently used to 
diagnose IMDs. The requirement of disease characteristic symptoms as a diagnostic 
criterion is problematic because they tend to reflect irreversible tissue damage. 
Hence, the optimal time for treatment is often missed. In addition, the absence of 
one biomarker to confirm the diagnosis causes delayed, or even missed, detection of 
patients with IMD. These together result in abundant functional disability and a loss 
in quality of life.  
 16 
Multiple laboratory tests are currently used to evaluate immune functions in order 
to improve timely diagnosis of IMDs. For example, serum autoantibodies against 
citrullinated protein antigens (ACPA), rheumatoid factor (RF; immunoglobulin M, 
IgM or IgA) and traditional markers for acute phase response (erythrocyte 
sedimentation rate, ESR and C-reactive protein, CRP) are considered the most 
important laboratory tests for RA diagnosis. In addition, novel biomarkers such as 
autoantibodies against carbamylated proteins (anti-CarPs) and autoantibodies against 
peptidyl arginine deiminases isoforms (anti-PADs) are recently reported and might 
aid clinical decision-making in the future. However, all of the aforementioned 
markers can also be found during adequate immune functions. In other words, they 
all lack sufficient sensitivity for immune dysregulation. New biomarkers are hence 
urgently needed to improve early detection of IMDs. Moreover, a better 
understanding of the underlying pathogenesis is required to develop specific 
treatment strategies that would match with the particular pathophysiological profile. 
Proprotein convertase subtilisin/kexin (PCSK) enzymes regulate general 
homeostasis by dictating the bioactivity of several secretory proteins. Furin is the 
first identified, and hence best studied, PCSK enzyme and has been shown to be 
predominantly upregulated during immune activation. Both adaptive and innate 
immune cells express Furin, but its fundamental regulatory role in immune response 
continues to be poorly understood. Lipopolysaccharide (LSP) – a characteristic 
component of gram-negative bacteria – is known to stimulate Furin expression in 
acute infection, where it enhances toll-like receptor processing and promotes T 
helper (TH) cell polarization toward TH type 1 response. In addition, TH-cell-
expressed Furin has been proved to play an essential role in the maintenance of 
immunological tolerance, as it regulates the functional maturity of anti-inflammatory 
transforming growth factor beta 1 (TGF-β1) and is critical for the development of 
T regulatory (Treg) cells. The fact that Furin is secreted from activated immune cells 
makes it relatively easy to measure. This has pointed out an interesting aspect 
considering the use of Furin measurements in clinical practice. Its altered expression 
has previously been associated with several pathological conditions, such as chronic 
inflammation in atherosclerosis, aggressive metastatic cancer, and Alzheimer’s 
disease. However, its potential value as a biomarker for IMDs has not yet been 
evaluated.  
The main aim of this doctoral thesis is to investigate the potential role of Furin 
as a biomarker for three IMDs, including acute infection, primary Sjögren’s 
syndrome (pSS), and RA. This research is directly focused on estimating its usability 
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in diagnostics, assessing the disease activity, and evaluating the prognosis and 
treatment response.  
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2 REVIEW OF THE LITERATURE 
2.1 The innate immune system 
Innate immunity is the most primitive unit of immunity and is present in every plant 
and animal (Flajnik & Kasahara, 2010). It is characterized with its rapid response and 
operation in first-line defense against commonly encountered pathogens. Innate 
immune cells are also essential in the clearance of nonfunctional particles, such as 
cellular debris and damaged or dysregulated host cells. By maintaining a convenient 
milieu for cell function and proliferation it promotes the survival of appropriately 
operating cells. It is worth noting that innate immunity lacks the ability for specificity 
and sustainability, which results in limited acts in host defense. Activation of innate 
immunity leads to similar functions in spite of the initial activator, and these acts 
cannot be enhanced during lifetime (Murphy & Weaver, 2017). 
Since we are constantly surrounded by various potentially life-threatening 
microorganisms, the most beneficial method to avoid pathogen invasion is to deny 
their access in the very beginning. The initial barriers include physical, chemical, and 
biological shields that are together responsible for providing sufficient barrier 
permeability. Skin and mucosa form a physical fence, fatty acids create a 
disadvantageous milieu for proliferation, and microorganisms of normal flora act as 
natural competitors for intruders, for example. Consequently, only a fraction of 
external threats are able to enter the body in the first place (Elias, 2007;  Murphy & 
Weaver, 2017). However, even when pathogens are successful in breaking the first-
line barriers, they rarely manage to cause significant host tissue damage. This is due 
to innate immune cells and the highly organized complement system, which provide 
rapid second-line defense if necessary. They reside in tissues or circulate in the 
bloodstream to provide a comprehensive detection of any imbalance in general 
homeostasis. They also play a key role in the initial battle against internally generated 
threats, for example, deregulated tumor cells that could easily take over tissues if not 
suppressed. Once activated, additional innate units are recruited at a great rate to 
strengthen this second-line immune response in the infection site (Rivera, Siracusa, 
Yap, & Gause, 2016). 
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One of the most significant facilities in providing accurate immune functions is 
the ability to distinguish self from nonself and functional from nonfunctional 
particles. Innate immune cells express nonspecific pattern recognition receptors 
(PRRs) that recognize general danger signs, including pathogen- and damage-
associated molecular patterns (PAMPs and DAMPs). PAMPs are present on the 
surface of common invasive microbes, whereas DAMPs are released from host cells 
during cell stress or cell death (Akira, Uematsu & Takeuchi, 2006; Coers, 2013; 
Matzinger, 1994) . Human PRRs are further classified into several receptor types in 
accordance with their location and detection specialties. For example, toll-like 
receptors (TLRs) represent a class of transmembrane receptors, whereas nucleotide-
binding oligomerization domain (NOD)-like receptors (NLRs) are expressed in the 
cell cytoplasm (Franchi, Warner, Viani, & Nuñez, 2009; Kawai & Akira, 2010). In 
general, PRR ligation causes changes in receptor structures, which initiates 
intracellular signaling and eventually results in innate immune cell activation (Akira 
et al., 2006; Coers, 2013; Matzinger, 1994). It is worth noting that innate immune 
cells represent limited detection capacity because of their lack of specific features. 
They recognize common pathogens and damaged host cells but cannot provide 
antigen-targeted immune functions or immunological memory. Consequently, 
adaptive immunity is often needed to eliminate invaders, expressing more advanced 
defense mechanisms. For example, Mycobacterium tuberculosis and Chlamydia 
trachomatis are able to survive and replicate inside host cells where they cannot be 
found by innate immune cells (Byrne & Ojcius, 2004; McDonough, Kress, & Bloom, 
1993). In these circumstances, adaptive immunity is essential in complementing 
immune acts to secure effective host defense (Joffre, Nolte, Spörri, & Sousa, 2009). 
The complement system is a highly organized network comprising a number of 
soluble proenzymes. It is designed to enhance both innate and adaptive immune 
functions and operates in both extracellular and intracellular space. Its soluble units 
are organized into an amplifying proteolytic cascade where every activated enzyme 
activates several new proenzymes. The activation can be induced by classical, 
alternative, or lectin pathway, each leading to the generation C3 convertase and 
formation of active components C3a and C3b. The final effector functions include 
pathogen tagging via opsonization (C3b), formation of membrane attack complex 
(C5b-9), release of anaphylatoxins (C3a, C4a and C5a), and finally the activation of 
adaptive immune responses. However, it is noteworthy that complement activation 
is important also during normal homeostasis as it constantly detects and silently 
eliminates apoptotic cells and cell debris without activating other immune 
components (Merle, Church, Fremeaux-Bacchi, & Roumenina, 2015).  
 20 
2.1.1 The cells of the innate immune system 
Innate immune cells include phagocytes, granulocytes, natural killer (NK) cells, and 
innate lymphoid cells (ILCs) (Kvell, Cooper, Engelmann, Bovari, & Nemeth, 2007; 
Murphy & Weaver, 2017; Sonnenberg & Artis, 2015). They are specialized to identify 
and eliminate distinct pathogen types by expressing various effector mechanisms. All 
immune cells are originally derived from hematological stem cells in bone marrow. 
However, the later division into different maturation pathways explains their diverse 
functions in host defense. The division into myeloid and lymphoid lineages occurs 
in the very early phase of maturation. Myeloid progenitors give rise to phagocytes 
and granulocytes, whereas NK cells and ILCs originate from lymphoid stem cells 
simultaneously with adaptive immune cells, hence expressing rather lymphocyte-like 
actions (Fogg et al., 2006; Kvell et al., 2007; Sonnenberg & Artis, 2015).  
Phagocytes are specialized to eliminate foreign fragments by engulfing and 
dissolving them in their intracellular vesicles. These cells are further classified into 
macrophages, neutrophils, and dendritic cells (DCs) according to their special mode 
of operation in immune defense (Murphy & Weaver, 2017). Macrophages lodge in 
tissues and are often described as general scavengers, forming the basis for cellular 
innate immunity. They either reside in common colonization sites or circulate in the 
bloodstream to enable fast detection of any imbalance in general homeostasis. They 
are important not only in the clearance of pathogens but also in the elimination of 
abundant host material in noninfectious stages (Wynn, Chawla, & Pollard, 2013).  
M1 macrophages are mainly upregulated during pathogen invasion and characterized 
by proinflammatory functions, whereas M2 macrophages rather suppress 
inflammation and participate in tissue repair. After the detection of pathogens, 
activated M1 macrophages secrete chemotactic molecules to attract other immune 
cells to the infection site (Gordon, Plüddemann, & Martinez Estrada, 2014).  
Neutrophils are known for providing the first-line cellular defense and have a 
pivotal role in limiting infection in the very beginning. They are present in the 
bloodstream in large quantities and, hence, can quickly amplify innate immune 
responses after being recruited from surrounding vessels (Nathan, 2006). 
Other granulocytes include eosinophils, basophils and mast cells. These cells can 
be distinguished because of their numerous cytoplasmic granules. The identification 
of intruders stimulates intracellular vesicles and the plasma membrane to fuse. As a 
result, various toxic enzymes are release into the extracellular space. That is to say, 
granulocytes are specialized to destroy extracellular pathogens too large for 
phagocytosis (Stone, Prussin & Metcalfe, 2010). 
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DCs have an important role in enhancing innate immune responses, but because 
of their relatively slow migration, their functions are more significant in the later 
stages of infection. DCs are essential in mediating signaling between the innate and 
adaptive immune systems. After engulfing pathogens, they can display pathogen-
specific structures, which are referred to as antigens, in their distinctive cell-surface 
proteins. Next, they migrate to secondary lymphatic organs to activate naive adaptive 
immune cells. DCs also participate in defining the nature of the initiated adaptive 
immune response by secreting cytokines that coordinate T cell differentiation. This 
ensures the generation of optimal adaptive defense against a particular microbial 
attack. Because of their regulatory functions, DCs are also known as professional 
antigen-presenting cells (APCs; Joffre, Nolte, Spörri, & Reis e Sousa, 2009). 
NK cells and the recently identified helper-type group 1 (ILC1), group 2 (ILC2), 
and group 3 cells (ILC3) are referred to as innate lymphoid cells (ILCs), and they 
differ markedly from other innate immune cells.  They originate from lymphoid 
lineage and resemble adaptive lymphocytes in structure and production of cytokines. 
Nevertheless, because of the lack of antigen-specific receptors ILCs are still classified 
as a part of the innate immune system (Kvell et al., 2007). NK cells circulate in the 
bloodstream and are specialized to recognize and eliminate cells missing general 
“self”-markers, which are also known as major histocompatibility complexes 
(MHCs; Vivier et al., 2011). MHC class I molecules are found on the cell surface of 
every nucleated cells, whereas MHC class II molecules are only present on DCs, 
macrophages, and B cells. Because of the extensive polymorphism and polygenic 
trait of MHC genes, all organisms express their individually structured MHCs. They 
are used to distinguish host cells from foreign and potentially harmful cell types 
(Murphy & Weaver, 2017). When NK cells detect a distinct or decreased number of 
MHC class I molecules, they destroy these cells using direct cytotoxicity. Hence, NK 
cells are often described as the innate version of adaptive cytotoxic T cells (Vivier et 
al., 2011). In contrast, ILC1, ILC2, and ILC3 are specialized to amplify the 
surrounding cell signaling in order to strengthen the innate response. They are often 
found residing in colonization sites, such as the lungs, gut, and dermis, rather than 
circulating in the bloodstream. They orchestrate early phase immune response and 
are suggested to provide initial TH functions during the generation of complete 
adaptive immune response (Artis & Spits, 2015). 
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2.2 The adaptive immune system 
The adaptive immune system was developed in jawed predators roughly 500 million 
years ago as a competitive advantage to meet the demands of abundant pathogen 
supply. Because of evolutionary aspects, adaptive immunity is present only in 
vertebrates (Flajnik & Kasahara, 2010). It is characterized by highly destructive 
antigen-targeted functions and has the ability to generate long-lasting protection. In 
general, the adaptive immune system can be described as a competent host defense 
backup system for innate immunity. Notable, adaptive immune response is relatively 
slow and takes rather days, or even weeks, to fully establish. This underlines the 
importance of innate immune functions in the first-line defense (Murphy & Weaver, 
2017). 
T and B lymphocytes are the main operators of adaptive immune response. They 
both originate from hematopoietic stem cells in the bone marrow but differ in terms 
of further maturation and final effector functions. Activated B cells differentiate into 
short-lived plasma cells or long-lived memory: both are specialized to express and 
secrete antigen-specific antibodies (Pieper, Grimbacher, & Eibel, 2013).  In contrast, 
activated T cells provide fairly distinct effector mechanisms on the basis of the T cell 
subset. Cytotoxic CD8+ T cells act as direct cell-to-cell killers and facilitate host 
defense against deregulated tumor cells and intracellular pathogens. CD4+ TH cells, 
in turn, differentiate into various effector subgroups depending on the current tissue 
microenvironment and epigenetic factors. They are responsible for orchestrating 
responses of both innate and adaptive immune cells. (Pearce, 2003; Zhu, Yamane, 
& Paul, 2010)  
The ability to differentiate into T and B memory cells enable long-lasting host 
defense and faster responses in reinfections. As a consequence, the adaptive immune 
system can improve its defense capacity to match with the present microbial supply 
during lifetime. (Murphy & Weaver, 2017). It is utilized in vaccinations, where 
lifelong resistance against well-known harmful, or even lethal pathogens, is generated 
artificially (Bevan, 2011; Pulendran & Ahmed, 2011).   
Lymphocytes are activated trough cell-surface antigen receptors TCRs and BCRs. 
In contrast to innate PPRs, adaptive recognition receptors are specific to only one 
particular antigen structure. Because of the wide polymorphism of receptor genes 
and random rearrangement of receptor structures, the final receptor loci can vary 
endlessly. Ultimately, the generated repertoire of adaptive recognition receptors is 
able to detect any antigen (Murphy & Weaver, 2017; Pieper, Grimbacher, & Eibel, 
2013). However, antigen receptor ligation is not sufficient alone to trigger 
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lymphocyte activation and differentiation. Instead, a simultaneous second signal is 
needed to amplify this initial TCR/BCR signaling. Costimulatory receptors, CD40 
for B cells and CD28 for T cells, are located on cell surfaces of cells designed to 
facilitate lymphocyte activation to ensure definite need for activation. The 
costimulatory ligands for CD28, CD80 and CD86, are predominantly found on cell 
surfaces of professional APCs. Correspondingly, the counterparts for CD40 is 
present only on TH cell surfaces. Therefore TH cells are essential  in the generation 
of effective humoral response (Dong et al., 2001; Murphy & Weaver, 2017; 
Schoenberger et al., 1998).  
2.2.1 T cell development 
After the division into myeloid and lymphoid lineages in the bone marrow, a group 
of common lymphoid progenitors (CLPs) migrate to the thymus for further 
maturation.  The altered nature of signaling promotes encoding of T cell genes and 
results in the generation of TCR chains and T-cell-type cell surface markers including  
CD3, CD4 and CD8 (Kondo, Scherer, King, Manz, & Weissman, 2001). After series 
of sequential changes, all pre-T cells end up expressing CD4 and CD8 on their cell-
surfaces. The double-positive cells (CD4+ and CD8+ T cells) migrate into the 
corticomedullary junction to undergo receptor testing through the mechanisms of 
central tolerance (Shortman & Wu, 1996).  
Thymic epithelial cells express plenty of MHC molecules and are responsible for 
the initial antigen presenting during the positive selection. Coreceptor stimulation 
promotes its own transcription and displaces the other coreceptor type. As a result, 
two single-positive T cell lines are generated; CD4+ TH cells and CD8+ cytotoxic T 
cells. Ultimate double positivity indicates nonfunctional surface receptors and these 
cells are guided into apoptosis via clonal deletion (Murphy & Weaver, 2017; Yamane 
& Paul, 2013; Zhu, Yamane, & Paul, 2010). After the positive selection the generated 
single-positive T cells move into the thymic medulla to undergo tests for 
autoreactivity. Thymic medullary cells encode the autoimmune regulatory (AIRE) 
gene to produce common self-peptides and display them to developing T cells.  All 
T cells with high affinity TCRs to the presented autoantigens are deleted in the 
mechanisms of negative selection. Finally, single-positive T cells passing both 
positive and negative selection are hauled to the bloodstream (Abramson, Giraud, 
Benoist, & Mathis, 2010; Yamane & Paul, 2013). 
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2.2.2 T cell function 
Naive T cells circulate between lymphatic organs to seek out their specific antigen. 
In general, CD4+ TH cells detect antigen-MHC class II complexes presented by 
APCs whereas CD8+ cytotoxic T cells recognized antigens bind to MHC class I 
molecules presented by several cell types (Miles, McCluskey, Rossjohn, & Gras, 
2015). TCR signaling combined with amplifying TCR associated co-receptor 
signaling leads to induction of T cell activation. Activated lymphocytes proliferate 
and differentiate into distinct effector T cells in guidance of the strength of TCR 
signaling, the surrounding cytokine environment and epigenetic regulation (Yamane 
& Paul, 2013). 
Activated DCs and CD4+ T cells provide the required second signals for CD8+ 
T cells and, hence, regulate the generation of cytotoxic T cell response. Once 
activated, CD8+ T cells undergo excessive proliferation and develop their 
characteristic effector functions. These include, for example, the activation of FAS-
ligand-mediated apoptosis, secretion of toxic enzymes such as perforin and 
granzyme B, and production of interferon gamma (IFN-γ), which inhibits viral 
replication and stimulates macrophage functions in order to promote more effective 
pathogen clearance (Pearce et al., 2003; Topham, Tripp & Doherty, 1997). (Chang, 
Wherry & Goldrath, 2014). 
On the contrary, only cells that express MHC class II molecules and the 
mandatory TCR signal amplifiers, CD86 and CD80, are able to activate CD4+ T 
cells. These cells include macrophages, DCs and B cells of which are, hence, referred 
to as professional APCs (Miles et al., 2015; Murphy & Weaver, 2017). Even though 
B cells and macrophages can equally initiate CD4+ T cell activation, DCs are stated 
as the most Hence initial PRR signaling guides DC actions in order to achieve 
maturation of the most needed CD4+ T cell subset regarding the particular attacker 
type. Finally, mature TH cells leave secondary lymphatic organs and migrate to their 
specific operating sites (Yamane & Paul, 2013; Zhu et al., 2010). 
TH1 response is generated in the presence of IL-12 and IFN-γ via signal 
transducer and activator of transcription 1/signal transducer and activator of 
transcription 4 (STAT1/STAT4)-mediated signaling pathways and is designed to 
enforce immune responses against intracellular pathogens. TH1 cells produce IFN-
γ, which promotes macrophage activation. In addition, TH1 cells guide antibody class 
switching toward opsonizing IgG-type antibodies to result in even more effective 
phagocytosis (Szabo, Sullivan, Peng, & Glimbcher, 2003). 
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TH2 response, in turn, is generated via the IL-4/STAT6 pathway to strengthen 
immune defense against extracellular invaders too large for engulfment such as 
parasites. TH2 cells enforce immunity especially in mucosal surfaces, where they 
secrete IL-4, IL-5, and IL-13 to lure and activate circulating granulocytes. In addition, 
TH2 cells favor IgE class switching to boost granulocyte functions (Yamane & Paul, 
2013; Zhu et al., 2010). 
The third main TH-cell-type response is generated in the presence of IL-6, IL-23 
and TGF-β via the STAT3 signaling pathway to promote efficient clearance of 
extracellular pathogens in common barrier sites such as the gut, lungs, and urogenital 
tract. Mature TH17 cells produce IL-17 and IL-22, which attract neutrophils, 
stimulate the local epithelial cells to produce antimicrobial peptides, and prevent 
further pathogen invasion. In addition, TH17-cell-type response favors IgG class 
switching and supports effective pathogen detection (Crome, Wang, & Levings, 
2010; Zuniga, Jain, Haines, & Cua, 2013). 
TFH and Treg cells develop alongside all previously described TH cells but differ 
greatly in terms of their fundamental functions in host defense. TFH cells are 
mandatory in generating T-cell-dependent antibody responses in germinal centers 
(GCs). Their maturation comprises multiple stages and involves several promoting 
factors including IL-6, IL-21, inducible T cell co-stimulator (ICOS), and TCR 
signaling. Expression of the transcription factor B-cell lymphoma 6 (Bcl-6) and cell-
surface C-X-C motif chemokine receptor type 5 are considered hallmarks of TFH cell 
polarization and play a mandatory role in TFH cell migration (Crotty, 2014). Unlike 
other T cell types, mature TFH cells stay in secondary lymphatic nodes. They move 
to B cell zones to provide costimulatory signaling for B cells through CD40 ligation; 
facilitate B cell differentiation, proliferation, and survival in GCs; and produce B-
cell-stimulating cytokines such as IL-21 and IL-4 (Deng, Wei, Fonseca, Graca, & Yu, 
2019). TFH cells are essential for the generation of effective B cell functions trough 
the GC formation and affinity maturation of antibodies (Murphy & Weaver, 2017; 
Vinuesa, Linterman, Yu, & MacLennan, 2016). 
Treg cells, in contrast, are important in providing suppressor functions. They 
rather restrain than promote inflammation and have a key role in preventing 
exaggerated immune responses. Natural T regulatory (nTreg) cells are formed in the 
thymus as part of positive and negative selection, and they represent a group of T 
cells with the highest affinity for self-antigens still able to pass negative selection 
criteria. In addition to nTreg cells, DCs assist differentiation of induced T regulatory 
(iTreg) cells via STAT5-mediated pathway in the presence of IL-2 and TGF-β to 
provide better control for erroneous immune cell functions in periphery (Pieper et 
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al., 2013). The ability to express transcription factor forkhead box P3 (FoxP3) in 
response to self-antigens has been reported as the determining factor in protective 
functions of Treg cells (Fontenot et al., 2005). In general terms, Treg cells limit 
inflammation by producing anti-inflammatory IL-10 and TGF-β that prevent 
antigen presentation and inhibit costimulatory signaling in order to restrain the 
activation and enforcement of other TH cell responses. They also express high-
affinity IL-2 receptors and hence restrict general availability of IL-2, a significant 
inducer of TH cell activation (Josefowicz, Lu, & Rudensky, 2012; Maynard et al., 
2007). 
Moreover, recent studies have reported new TH cell subgroups including TH9 and 
TH22 cells, which both are suggested to participate in protective immunity. However, 
the fundamental role and operation of these new TH cell types remain unclear 
(Raphael, Nalawade, Eagar, & Forsthuber, 2015). 
In conclusion, professional APCs are essential in regulating the activation of T 
cells and initiation of a cell-mediated immune response. DCs produce a selection of 
cytokines to reflect encountered invaders in order to guide TH cell polarization 
toward the most suitable TH cell type ( Joffre et al., 2009). Mature TH cells orchestrate 
innate and humoral responses through their cytokine secretion. They enforce the 
prevalent immune response by favoring their own polarization and inhibiting 
polarization of others TH cell subgroups. Consequently, TH cell polarization is 
continuously changing state that reflects the current internal and external needs. It is 
essential to restore the general balance in order to prevent TH cell deregulation and 
maintain general homeostasis (Zhu et al., 2010). The general characters of the 
discussed TH subpopulations are summarized in Figure 1.  
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Figure 1.  CD4+ T cell differentiation and function. Activation of a naive CD4+ T cell can be divided 
into a TCR-driven induction and a cytokine-driven polarization phase. Interaction between 
naive CD4+ T cell and an antigen-MHC class II complex presented by a professional APC 
leads to a significant increase in TCR signaling. This, together with correct second signals 
result in the induction of T cell activation. Present cytokine environment guides T cell 
polarization by activating specific STAT signaling pathways and leading to the production of 
a unique transcription factor repertoire. Mature CD4+ T cell subpopulations are 
characterized with a specific cytokine secretion that reflects their final effector functions. The 
figure is adapted from O´Shea, Tato, & Siegel, 2008 and Oksanen,2012. (O´Shea, Tato, & Siegel, 2008; Oksanen, 2015) 
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2.2.3 T cell plasticity 
Various CD4+ T cell responses are produced in response to encountered pathogens 
in order to ensure well-targeted actions and optimized immune responses for 
pathogen clearance. However, a majority of microbes are able to generate additional 
defense mechanisms to shelter themselves and contribute to survival. TH1 and TH2 
cells represent relatively stable cell lines. On the contrary, studies have reported 
rather flexible phenotypes of TH17 and Treg cells as they are able to repolarize in 
response to changes in present cytokine environment. Th17 cells have been reported 
to turn into TH1 cells in the presence of IL-12 or IL-23, whereas proinflammatory 
cytokines guided Treg cells to turn into TH1 or TH17 cells. The ability for T cell 
plasticity enables relatively fast alterations in TH-cell-mediated immune responses in 
order to keep up with the constantly changing demands (Murphy & Stockinger, 
2010; O´Shea & Paul, 2010; Wing & Sakaguchi, 2010). 
2.2.4 B cell biology  
B cells originate from the same CLPs with T cells but instead of migrating to the 
thymus, they are kept in bone marrow for further maturation. Surrounding signaling 
promotes B cell gene encoding and induces the generation of characteristic BCRs. 
Because of the random rearrangement of BCR units, the final structure of receptor 
locus can vary extensively. Hence, the accurate B cell functions need to be tested 
carefully. Similar to T cells, general functionality is tested first via positive selection, 
and this is followed by autoreactivity tests via negative selection. In case of failure in 
central immunological tolerance tests, the cells can be returned to receptor editing. 
However, in case of multiple failures, they are driven to clonal deletion. Eventually, 
all B cells with accurate receptor functions can be released to the circulation (Kondo 
et al., 2001). 
Newly produced naive B cells cannot live long in the bloodstream, which is why 
they are swiftly transported into secondary lymphatic organs where they reside in 
distinctive B cell zones. Lymphatic follicular cells express B cell activation factor 
(BAFF), which is critical for B cell differentiation, proliferation, and survival (Mackay 
& Browning, 2002; Pieper et al., 2013; Schiemann et al., 2001). The inflow of antigens 
contributes to the antigen–BCR attachment, which leads to the activation of B cells 
and production of soluble antibodies also known as immunoglobulins. Furthermore, 
activated B cells are shed to the circulation, and they migrate to infection sites where 
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they produce proinflammatory cytokines to enforce the local immune response 
(Pieper et al., 2013). 
Notably, individual BCR signaling is only able to stimulate the production of IgM 
class antibodies, which are characterized by a relatively fast expansion but can only 
express low-affinity binding sites and limited effector functions. The second 
signaling from activated TFH cells is essential for further enhancement of antibodies 
(Breitfeld et al., 2000; Reinhardt, Liang, & Locksley, 2009). Moreover, TFH cells 
regulate the differentiation of B cells and allow the production of long-lasting 
memory B cells. The B cell–TFH cell interaction is, hence, pivotal for the persistent 
immunity and the ability for faster antibody-mediated responses in terms of 
reinfection (Bevan, 2011; Murphy & Weaver, 2017; Pulendran & Ahmed, 2011). 
As discussed earlier, TH cells produce cytokines that guide Ig class switching and 
somatic hypermutation to improve both the affinity and functional capacity of 
produced antibodies. As a consequence, they are able to reflect the pathogen type 
and can provide targeted functions for a more effective clearance. Human Ig classes 
include IgG, IgM, IgA, IgD, and IgE antibodies; all of them differ from each other 
in terms of their effector functions and operation sites (Papavasiliou & Schatz, 2002; 
Schoenberger et al., 1998; Stavnezer, 1996). ). In general terms, they can be divided 
into neutralizing, opsonizing, and complement-activating antibodies. In further 
detail, neutralizing antibodies block pathogen invasion and protect cells from 
intracellular infections, whereas opsonizing antibodies are able to mark pathogens 
for phagocytosis. Complement-activating antibodies are, in turn, specialized to 
facilitate complement functions through classical pathway activation (Murphy & 
Weaver, 2017). 
2.2.5 Immunological tolerance  
Because of potentially destructive acts of adaptive immune cells, the accurate 
identification of harmless and harmful operators is essential for survival. Pathogens 
that contain structures resembling host tissues create a particular challenge for 
recognition, as immune cells must be able to detect and eliminate them sufficiently 
but able to simultaneously avoid abundant response against self-structures. This state 
of balance in ignoring self is generally referred to as immunological tolerance. It is 
classically divided into central and peripheral tolerance; both contain several 
mechanisms that together ensure correct adaptive immune cell activation (Murphy 
& Weaver, 2017). 
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Mechanisms of central tolerance take place at the beginning of the development 
of lymphocytes. They consist of lymphocyte receptor testing and are divided into 
two stages called positive and negative selection. Positive selection confirms the 
general receptor functionality, whereas negative selection is important for detecting 
unpleasantly reacting immune cells. More specifically, tissue-specific antigens are 
displayed to newly formed lymphocytes during negative selection in order to edit or 
delete strongly autoreactive immune cells. Because of the ability to express the AIRE 
gene, thymic epithelial cells are able to create and present multiple self-antigens to 
pre-T cells. All highly activated lymphocytes are driven straight into apoptosis, 
whereas cells expressing affinity just less than the elimination limit are saved as 
potentially autoreactive cells and continue their development to nTreg cells 
(Abramson et al., 2010; Von Boehmer & Melchers, 2010). 
Because of the limited capacity of the AIRE gene, all tissue types cannot be 
present during negative selection. As a result, some autoreactive lymphocytes are still 
able to escape the central mechanisms and released to the circulation. In addition, 
various triggers such as environmental stress or cell aging can affect lymphocyte 
signaling pathways and lead to deregulated immune cell activation. Therefore, the 
checkpoints of peripheral tolerance are crucial in completing the central 
mechanisms. The most primitive method of peripheral tolerance is to simply keep 
adaptive immune cells away from self-tissue antigens. Naive B and T cells lodge in 
their characteristic zones in secondary lymphoid tissues where anti-inflammatory 
conditions are maintained by the presented Treg cells. The continuous inflow of 
innate immune cells provides low-grade TCR and BCR signaling but lacks mandatory 
costimulatory messages. (Eberl, 2016; Murphy & Weaver, 2017). Moreover, because 
PRR-mediated intracellular signaling is needed for the expression of cell-surface 
costimulatory CD80 and CD86 receptors in APCs, the perception of individual TLR 
signaling indicates that the antigen is not presented by activated professional APCs. 
In contrast, it reflects that adaptive immune response activation is currently not 
needed. This activates another intracellular signaling pathway, which leads to the 
production of the anti-inflammatory cytokine IL-10 and drives lymphocytes to a 
functionally inactive state called anergy (Eberl, 2016; Macián, Im, García-Cózar, & 
Rao., 2004). 
On the contrary, accurate lymphocyte activation stimulates adaptive immune cells 
to migrate into peripheral tissues wherein they are exposed to various self-antigens. 
Activated immune cells tend to enforce the functions of each other by creating a 
nonresolving cycle if not restricted. Hence, Treg cells are critical in regulating 
activated immune cells in the periphery. They limit inflammation and prevent 
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excessive damage by arresting lymphocyte actions in conditions where there are no 
signs of danger (Josefowicz et al., 2012). The suppression of potentially autoreactive 
cells strengthens the eventual immune response by establishing the maintenance of 
sufficient detection capacity against pathogens resembling host cells. 
In addition to extrinsic suppressive messages from Treg cells, all immune cells are 
encoded with intrinsic self-limiting mechanisms to avoid excessive and prolonged 
inflammation. These signaling pathways are induced parallel to activation signals and 
lead to self-driven apoptosis after a certain period of time. Further, cells presenting 
exceptionally strong activation messages are promptly guided into apoptosis (Eberl, 
2016). 
In conclusion, immunological tolerance includes several checkpoints that assure 
the correct operation of the immune system. Cells expressing misleading functions 
are rapidly eliminated to prevent any harmful actions. Adaptive immune cells provide 
distinct effector functions that provide a conclusive clearance of various invasive 
pathogens. Immunological tolerance enables the maintenance of representative 
receptor collection and has a key regulatory role as an inflammation suppressor 
(Eberl, 2016; Murphy & Weaver, 2017). However, the breakdown of immunological 
tolerance allows immune cells to mount full-force responses against host cells and 
results in a significant self-tissue damage and unpredictable outcomes. An 
uncontrolled function of the immune system can lead to the generation of IMDs 
(DuPage & Bluestone, 2016). 
2.3 Immune-mediated diseases 
The failure of immunoregulation can lead to can lead to a breakdown in peripheral 
tolerance and cause various pathogenic conditions referred to as immune-mediated 
diseases (IMDs). These include, for instance, immunodeficiency, hypersensitivity, 
excessive inflammation, and autoreactivity. Fundamentally, redundant self-tissue 
damage caused by deregulated immune cells can be described as the connecting 
factor in all stated disorders (Murphy & Weaver, 2017). In this chapter, the 
pathogenesis and clinical features of three distinct IMDs are discussed in detail, 
including sepsis, pSS and RA.  
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2.3.1 Infectious diseases and development of sepsis 
Sepsis is a life-threatening condition characterized by a dysregulated host response 
to an infection and subsequent generation of multiple organ dysfunction (MOF; 
Singer et al., 2016). It is a relatively common syndrome with a notably high mortality 
rate. A systematic review of published population-level assessments from 1979 to 
2015 extrapolated a present worldwide estimate of 30 million cases of sepsis and 6 
million deaths caused by it per year. Hospital mortality ranged from 17% to 26%, 
depending on the extensiveness of the affected organs (Fleischmann et al., 2016). 
Moreover, the survivors tend to suffer from long-term complications including 
impaired cognition, functional disability, and increased dependence. The lost 
productivity and increased need for health care services represent roughly 70% of 
the total patient costs, putting an exceptional economic burden on society (Tiru et 
al., 2015). In fact, the World Health Assembly and World Health Organization made 
sepsis a global health priority in 2017, calling states to pay further attention to 
improve the prevention and treatment of sepsis (Reinhart et al., 2017). 
The sepsis syndrome is a rapidly progressive, overwhelming systemic 
inflammatory response against any infectious pathogen, leading to disadvantageous 
changes in microcirculation and endothelial functions (Aird, 2003; De Backer, Ortiz 
& Salgado, 2010; Koh et al., 2010). The loss of suppressor effects and excessive 
production of proinflammatory cytokines create a vicious cycle, increasingly 
activating stimulatory immune system components, and result in exceptionally 
strong oxidative stress, vasodilatation, coagulopathy, and loss of endothelial barrier 
functions. This leads to hemodynamic instability, impaired mitochondrial function 
and anergy, together with extensive tissue damage and tissue edema; all of them 
together contribute to organ dysfunctions (Aird, 2003; Garcia-Alvarez, Marik & 
Bellomo, 2014; Levi, 2001; Singer, 2014). Common manifestations of organ 
dysfunctiona are, for example, acute respiratory distress syndrome, acute kidney 
injury, and encephalopathy (Matthay, Ware, & Zimmerman, 2012; Poston & Koyner, 
2019; Ziaja, 2013). Remarkably, within a few days, hyperinflammation is followed by 
a state of immunosuppression, making the body vulnerable to a potentially fatal 
second infection (Drewry et al., 2014;Otto et al., 2011; Walton et al., 2014). CD4+ 
and CD8+ cells are eliminated via apoptosis, and studies of spleens of patients who 
have died from sepsis show reduced production of cytokines and a significant 
decrease in T cell levels (Boomer et al., 2011; Hotchkiss et al., 2001). 
Despite multiple studies, the underlying reason for the loss of immune system 
control remains unclear. However, the most significant risk factors for sepsis 
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represent conditions with general susceptibility to infections, such as very young or 
old age, immunosuppressive diseases, cancer, diabetes, alcohol abuse, 
immunosuppressive medication, parenteral nutrition, and indwelling catheters.  
Furthermore, genetic factors, comorbidities, and certain features of the invasive 
pathogen are suggested to play a role in the generation of the syndrome. Clinical 
manifestations of sepsis vary considerably and depend mainly on the initial infection 
site. Most patients arrive in the emergency room (ER) suffering from nonspecific 
malaise and exhibit typical symptoms of suspected infection, including fever, 
tachycardia, tachypnea, and altered cognition (Cecconi, Evans, Levy, & Rhodes, 
2018). Comprehensive clinical examination and laboratory tests including lactate 
levels, white blood cell count, CRP, and procalcitonin are used to guide clinical 
decision-making. Moreover, because there is no specific biomarker for the sepsis 
syndrome, several classification criteria have been generated to facilitate the 
identification of sepsis from benign infections (Rhodes et al., 2017). 
The traditional classification criteria for sepsis were created by the American 
College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) in 
1991, focusing on recognizing general inflammation signs. The classification criteria 
defined sepsis as a condition with symptoms fulfilling at least two criteria for 
systemic inflammatory response syndrome (SIRS) and a positive blood culture 
sample. The term “severe sepsis” was used when sepsis was complicated by MOF 
and the term “septic shock” described conditions of severe sepsis and a significantly 
decreased mean arterial pressure (MAP; Bone, Sibbald & Sprung, 1992).  The 
classification criteria for SIRS are described in detail in Table 1. However, further 
studies showed poor sensitivity and specificity for SIRS in sepsis diagnostics and 
prompted the development of better standards (Levy et al., 2003). The Society of 
Critical Care Medicine and the European Society of Intensive Care Medicine 
announced the Third International Consensus Definition for Sepsis and Septic 
Shock (Sepsis-3) guidelines in 2016 (Singer et al., 2016). The terms “SIRS” and 
“severe sepsis” were eliminated, and the main focus was shifted from inflammation 
to organ dysfunctions, using the Sequential Organ Failure Assessment (SOFA) score 
described in Table 2 (Vincent et al., 1996).The new Sepsis-3 guidelines define sepsis 
as an acute infection presenting two or more SOFA scores. Henceforth, septic shock 
is used when sepsis is combined with lactatemia of more than 2 mmol/L together 
with the need of vasopressors in order to maintain MAP greater than 65 mm Hg to 
avoid critical hypoperfusion (Singer et al., 2016). 
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Table 1. The 1992 ACCP/SCCM Consensus Committee classification criteria for SIRS.a 
Two or more of the following criteria: 
 Body temperature >38°C or <36°C 
 Heart rate >90 beats per minute 
 Respiratory rate >20 breaths per minute or PaCO2 <32 mm Hg (4.3 kPa) 
 White blood cell count >12,000/mm3 or <4000/mm3 or >10% immature bands 
a Adapted from the ACCP/SCCM Consensus Committee classification criteria (Bone et al., 
1992).ACCP/SCCM = American College of Chest Physicians/Society of Critical Care 
Medicine; SIRS = systemic inflammatory response syndrome. 
 
 
 
Table 2. The sepsis-related Sequential Organ Failure Assessment score     
 
Score         
System 0 1 2 3 4 
Respiration           
     PaO2/FIO2  mm Hg (kPa) ≥400 (53.3)  <400 (53.3)  <300 (40)  
<200 (26.7) with 
respiratory support 
<100 (13.3) with 
respiratory support 
Coagulation      
     Platelets, ×103/μL  ≥150  <150  <100  <50  <20  
Liver           
    Bilirubin, mg/dL (μmol/L)  <1.2 (20) 1.2–1.9 (20–32)  2.0–5.9 (33–101)  
6.0–11.9  
(102–204)  >12.0 (204)  
Cardiovascular      
 
MAP 
≥70 mmHg 
MAP 
<70 mmHg 
Dopamine <5 or 
dobutamine 
Dopamine 5.1–15 or 
epinephrine ≤0.1 
Dopamine >15 or 
epinephrine >0.1 
   (any dose)a or norepinephrine  or norepinephrine  
    ≤0.1a >0.1a  
Central nervous system         
    GCS scoreb 15 13–14  10–12 6–9 <6 
Renal      
    Creatinine, mg/dL (μmol/L)  <1.2 (110)  
1.2–1.9  
(110–170)  
2.0–3.4 
 (171–299)  
3.5-4.9 
(300–440)  >5.0 (440) 
    Urine output, ml/d        <500  <200  
Adapted from the European Society of Intensive Care Medicine criteria (Vincent et al., 1996).  
a Catecholamine doses are given as μg/kg/min for at least 1 hour. 
b Scores range from 3 to 15; higher score indicates better neurological function. 
FIO2 = fraction of inspired oxygen; GCS = Glasgow Coma Scale; MAP = mean arterial pressure.  
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The international guidelines for the management of severe sepsis and septic 
shock define sepsis as a medical emergency, stating a need for urgent treatment. The 
most important aspects of improving patient prognosis include early detection, 
source control by removing infected tissues, and rapid initiation of appropriate 
intravenous antibiotic administration. Moreover, fluid resuscitation, vasopressors 
and inotropes, red blood cell transfusions, and glycemic control are used for general 
stabilization, but there is no evidence of their effects on the final outcomes (Rhodes 
et al., 2017). The mortality of sepsis is estimated to rise nearly 8% per hour of delay 
in the initiation of appropriate antibiotic treatment, making effective patient 
screening crucial (Anand Kumar et al., 2006). In parallel with the new Sepsis-3 
guidelines, experts developed a new clinical sepsis screening tool, the quick SOFA 
(qSOFA), to facilitate early detection and treatment administration. The criteria for 
positive qSOFA are provided in Table 3. It is designed for bedside use to indicate 
an increased risk of generating sepsis and is hence suitable for use also outside the 
intensive care unit. The fulfillment of two or more of the following criteria indicates 
a positive qSOFA score: alteration in mental status, systolic blood pressure ≤100 
mm Hg, or respiratory rate ≥22/min (Churpek et al., 2017). Although the qSOFA 
has improved the stratification of patients, it provides only indicative information of 
the presented condition and cannot be used for the exclusion of the sepsis syndrome. 
There is an urgent need for a specific early phase biomarker for the sepsis syndrome 
to allow for a more accurate detection of patients and possibly even a selection of 
targeted treatment strategies to match the individual pathophysiological profile. 
 
 
 
Table 3.  The qSOFA Score.       
Two or more of the following criteria:  
 Altered mentation   
 Respiratory rate ≥22 breaths per minute 
 Systolic blood pressure ≤100 mm Hg 
  
Adapted from the Third International Consensus Definition for Sepsis and Septic 
Shock (Sepsis-3; Singer et al., 2016). 
qSOFA = quick Sequential Organ Failure Assessment. 
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2.3.2 Primary Sjögren’s syndrome 
Sjögren’s syndrome (SS) is a systemic autoimmune disease characterized by 
irreversible exocrine gland destruction because of excessive lymphocyte infiltration. 
Salivary and lacrimal glands are mainly affected, leading to problematic symptoms of 
dry eye (keratoconjunctivitis sicca) and dry mouth (xerostomia). These are present 
in more than 95% of cases and are considered the hallmarks for SS (Ramos-Casals , 
Brito-Zerón, Sisó-Almirall, & Bosch, 2012; Vitali et al., 2002). In addition, SS may 
affect extraglandular organs involving for example skin, joints, lungs, heart, kidneys, 
and nervous system, and is associated with an increased risk of B cell lymphoma. 
Moreover, patients with SS tend to suffer from a set of nonspecific symptoms such 
as fatigue, anxiety, depression, and chronic pain. In summary, the clinical 
presentation of SS vary widely (Mavragani & Moutsopoulos, 2014; Nocturne & 
Mariette, 2013; Pillemer et al., 2009). 
SS is classically divided into two diagnostic groups on the basis of possible 
underlying diseases. Primary Sjögren’s syndrome (pSS) is a disease without other 
autoimmune comorbidities, whereas secondary Sjögren’s syndrome (sSS) is a 
condition where typical symptoms of SS develop after the diagnosis of an associated 
disease, such as systemic lupus erythematosus (SLE), RA, or systemic sclerosis 
(Ramos-Casals et al., 2012). The estimated prevalence of pSS varies between 0.1% 
and 4.8% depending on the diagnostic criteria used (Pillemer et al., 2001). It is nine 
times more common in females and has an incidence peak at the age of 40 to 50 
years (Mavragani & Moutsopoulos, 2010; Patel & Shahane, 2014). 
Despite extensive studies, the principal etiology of pSS remains elusive. It is 
currently suggested that an environmental factor such as a viral infection or 
deposition of immune complexes (ICs) might trigger undesirable lymphocyte 
functions in genetically susceptible individuals (Nocturne & Mariette, 2013). Genetic 
polymorphisms including STAT4, IFN regulatory factor 5 (IRF-5) and IL-12 subunit 
regulatory factor are associated with the development of pSS (Gestermann et al., 
2010; Lessard et al., 2014). According to current knowledge, the main 
pathophysiological mechanisms are mediated through IFN-I and IFN-II pathways 
(Nocturne & Mariette, 2013; Pollard, Cauvi, Toomey, Morrid, & Kong, 2013). Both 
signaling systems promote BAFF expression and hence maintain the continuous B 
cell activation. This leads to the continuous production of the autoantibodies anti-
Ro/Sjögren’s syndrome antigen A (anti-Ro/SSA) and anti-La/Sjögren’s syndrome 
antigen B (anti-La/SSB) distinctive for SS (Mariette et al., 2003; Vitali et al., 2002).  
BAFF maintains the production of IFN-α and forms a vicious circle that preserves 
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the pathological process (Nocturne & Mariette, 2013). Despite multiple studies, little 
is known about the fundamental reasons that lead to IFN-I system activation. 
However, at least to some extent, the elevated IFN-α expression has appeared to 
occur via human TLRs (Mavragani & Crow, 2010). The IFN-II pathway has been 
less studied even though the TH1 cytokine IFN-γ appears to be central in the 
pathogenesis (Pollard et al., 2013). The prevalence of IFN-γ is necessary for the 
evolution of gland dysfunction in Ro/SSA immunized mice (Nocturne & Mariette, 
2013). On the contrary, a decreased IFN-γ or IFN-γR level seems to inhibit the 
development of pSS (Pollard et al., 2013). IFN-γ expression is predominantly 
mediated through the IL-12/STAT4 pathway, which additionally seems to associate 
with an increased production of IFN-α, suggesting significant effects of IL-12 and 
STAT4 in the pathogenesis of pSS (Nocturne & Mariette, 2013). The ultimate failure 
of peripheral tolerance in pSS is caused by the decreased activity of anti-
inflammatory TGF-β1, which leads to abnormal T cell polarization, impaired Treg 
cell function, and increased production of TH1- and TH17-cell-type cytokines (Pesu 
et al., 2008). 
Because of an incomplete understanding of disease-mediated events in immune 
regulation, there is no specific and sensitive biomarker for pSS. In addition, the 
current estimating manners for disease activity are inaccurate and do not reflect 
changes effectively. The multitier sets of criteria are at present used to assist 
diagnosis. The criteria comprise typical symptoms together with the presence of 
characteristic autoantibodies Ro/SSA and/or La/SSB or, alternatively, the presence 
of lymphocytic sialoadenitis in minor salivary gland biopsy. It is worth noting that 
invasive diagnostic examinations, such as biopsies, should be avoided if possible 
(Vitali, 2002). The currently used classification criteria for pSS are presented in detail 
in Table 4. After diagnosis, the disease activity is estimated using questionnaire-based 
indexes; European League Against Rheumatism (EULAR) pSS patient-reported 
index (ESSPRI) and EULAR pSS disease activity index (ESSDAI) (Seror et al., 
2010). The complexity and nonspecificity of the used classification criteria lead to a 
delayed, or even missed, detection of patients with SS especially in the early phase of 
the disease. In addition, the currently used activity indexes react slowly and are 
inaccurate for the estimation of treatment outcomes. Hence, biological drugs cannot 
be directed to patients who benefit from them. As a matter of fact, the disease often 
appears to be resistant to antirheumatic drugs, and the treatment of pSS is still mostly 
symptomatic. The limited knowledge of the pathogenesis complicates the generation 
of new effective therapies (Ramos-Casals et al., 2012). 
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Table 4. The 2002 American–European classification criteria for pSS. 
      
Criteria needed for the classification of a patient as having definite pSS:  
     The fulfillment of at least one of the following definitions together with the absence of   
     potentially associated diseases (e.g. SLE, RA, type I diabetes, or multiple sclerosis) 
     and any of the exclusion criteria:    
          (a) The presence of any four of the six items as long as either item IV or VI is positive 
          (b) The presence of any three of the 4 four objective criteria items (III, IV, V or VI) 
      
Exclusion criteria:     
     (a) Past head and neck radiation treatment    
     (b) Hepatitis C infection     
     (c) Acquired immunodeficiency syndrome   
     (d) Pre-existing lymphoma     
     (e) Sarcoidosis     
     (f) Graft versus host disease     
     (g) Use of anticholinergic drugs (since a time shorter than fourfold the half-life of the drug) 
           
I. Ocular symptoms: A positive response to at least one of the following questions: 
     (a) Have you had daily, persistent, troublesome dry eyes for more than 3 months? 
     (b) Do you have a recurrent sensation of sand or gravel in the eyes?   
     (c) Do you use tear substitutes more than three times a day?     
II. Oral symptoms: A positive response to at least one of the following questions: 
     (a) Have you had a daily feeling of dry mouth for more than 3 months?  
     (b) Have you had recurrently or persistently swollen salivary glands as an adult?  
     (c) Do you frequently drink liquids to aid in swallowing dry food?  
III. Ocular signs: Objective evidence of ocular involvement defined as a positive result 
      for at least one of the following two tests:       
     (a) Rose Bengal Score or other ocular dye score (>4 in van Bijsterveld’s scoring system) 
     (b) Schirmer’s I test, performed without anesthesia (<5 mm in 5 min)   
IV. Histopathology:     
     Focal lymphocytic sialoadenitis in minor salivary glands (obtained through   
     normal-appearing mucosa) detected by an expert histopathologist, with a focus score ≥1,  
     defined as a number of lymphocytic foci (which are adjacent to normal-appearing  
     mucous acini and contain more than 50 lymphocytes) per 4 mm2 of glandular tissue 
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V. Salivary gland involvement: Objective evidence of salivary gland involvement defined  
    by a positive result for at least one of the following diagnostic tests:   
     (a) Unstimulated whole salivary flow (<1.5 ml in 15 min)     
     (b) Parotid sialography showing the presence of diffuse sialectasias (punctate,   
          cavitary, or destructive pattern), without evidence of obstruction in the major ducts 
     (c) Salivary scintigraphy showing delayed uptake, reduced concentration,    
          and/or delayed excretion of tracer       
VI. Autoantibodies: The presence of autoantibodies in the serum:   
     (a) Antibodies to Ro/SSA antigens    
     (b) Antibodies to La/SSB antigens    
     (c) Antibodies to Ro/SSA and La/SSB antigens      
Adapted from American-European Consensus Group criteria (Vitali, 2002).                                        
pSS = primary Sjögren´s syndrome; SLE = systemic lupus erythematosus; RA = rheumatoid arthritis. 
2.3.3 Rheumatoid arthritis 
RA is known as one of the most common autoimmune diseases worldwide, affecting 
roughly 1% of the population (Silman & Pearson, 2002). It is mainly diagnosed in 
women, with a female-to-male ratio of 3:1(Tobón, Youinou, & Saraux, 2010). The 
disease is characterized by chronic inflammation of the synovial compartment, which 
leads to a relatively fast bone and cartilage destruction. The main symptoms of RA 
include joint swelling, tenderness, and stiffness, which finally results in to joint 
deformity. RA symptoms are most commonly present in the wrists and small joints 
of hands and feet (Aletaha et al., 2010) However, it can also affect extra-articular 
organs such as the lungs, skin, eyes, exocrine glands, skeletal muscles, and heart 
(Friedewald et al., 2010; Turesson et al., 2003) and is connected to an increased risk 
of severe comorbidities including cardiovascular diseases, osteoporosis, and 
hematologic malignancies (Baecklund et al., 2006; Crowson et al., 2005; Kröger, 
Honkainen, Saarikoski, & Alhava., 1994). Because of the broad manifestation 
combined with problematic diagnostics and treatment, patients with RA are 
estimated to lose around 3 to 12 years of life compared to healthy individuals 
(Friedewald et al., 2010; Gabriel, 2008). 
The presence of serum autoantibodies against self-IgG-Fc (rheumatoid factor, 
RF) and ACPA are traditionally defined hallmarks of the disease (Aletaha et al., 
2010). However, one-third of patients do not have typical autoantibodies and are 
identified by expressing common clinical symptoms together with increased CRP or 
ESR levels, indicating an abnormal acute-phase reaction (Sieghart et al., 2018). 
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Extensive research suggests a broad selection of etiologies and pathological pathways 
in seronegative RA, whereas seropositive RA appears to be much more 
homogenous. Seropositivity predicts more severe symptoms but associates with a 
better response to disease-modifying antirheumatic drug (DMARD) therapy, 
indicating a potential role of autoantibodies in disease development (Firestein & 
McInnes, 2017). Because of a better understanding of immunopathological 
mechanisms behind seropositive RA, its pathophysiology is mainly discussed in this 
chapter. 
According to current knowledge, environmental factors such as long-term 
smoking or microbial infection might induce changes in posttranslational 
modification, which results in citrullination of self-proteins in mucosal surfaces 
(Klareskog et al., 2006; Meron et al., 2010). Consequently, autoreactive CD4+ TH 
cells bind to citrulline-coated self-proteins and activate a systemic autoimmune 
response. The propensity to lose self-tolerance is associated with susceptibility gene 
polymorphism, facilitating more sensitive CD4+ TH cell activation. HLA-DR allele 
that encode human leukocyte antigen (HLA) type II molecules with high-affinity 
binding groves is considered the main risk allele for RA (Gregersen, Silver, & 
Winchester, 1987). In addition, tyrosine-protein phosphatase nonreceptor type 22 
(PTPN22), STAT4 and cytotoxic T lymphocyte protein 4 (CTLA4) polymorphisms 
have been associated with disease development (Begovich et al., 2004; Gestermann 
et al., 2010;  Plenge et al., 2005; Remmers et al., 2007). Hypothesis of CD4+ TH-cell-
mediated pathogenesis is supported by excessive numbers of citrulline-specific T 
cells in the blood and accumulation of CD4+ TH cells in inflamed joints of patients 
with RA (Nell et al., 2005; Smolen Aletaha, & McInnes, 2016). The production of 
serum autoantibodies ACPA and RF reflects T-cell-mediated activation of residing 
naive B cells and sequential generation of a full-force systemic autoimmune response 
against citrullinated self-proteins. 
ICs of ACPA and RF accumulate in the synovial compartment and trigger local 
autoimmune responses in RA. They promote complement activation and stimulate 
innate immune cells to produce inflammatory mediators. Although the initiating 
factor that induces the transition from systemic to local disease remains unclear, 
vascular, neuroregulatory, microtrauma, and infection-dependent pathways are 
suggested to play a role in inducing tissue-specific autoimmunity in early stage RA 
(Firestein & McInnes, 2017). In addition to IC formation, ACPA induces a sensation 
of pain and promotes osteoclastogenesis directly by interacting with synovial 
osteoclasts (Krishnamurthy et al., 2016). The nature of signals facilitates osteoclast 
maturation and excessive lymphocyte infiltration. It also favors TH1/TH17-cell-type 
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polarization and leads to an increased activation of macrophages.  (Firestein & 
McInnes, 2017). Fibroblast-like synoviocytes on the surface of the synovium induce 
local inflammation by assisting antigen presentation, and secrete proteases and 
cytokines to mediate cartilage damage (Bartok & Firestein, 2010). Remarkably, the 
maturation of defective Treg cells is also associated with RA.  Failure in peripheral 
tolerance enables differentiation of autoreactive lymphocytes and generation of 
nonresolving synovial inflammation. (Byng-Maddick & Ehrenstein, 2014) 
An immunological basis of pathogenesis is supported by studies investigating 
immunological therapy in targeting the central pathological mediators. Patients are 
currently treated first with a combination of short-term glucocorticoid and general 
proliferation inhibitor methotrexate. However, because of incomplete treatment 
targeting, second line therapies are often needed and direct cytokine inhibitors 
together with suppressors of T and B cell activation are found to be beneficial in the 
treatment of RA. (Smolen, Aletaha, Koeller, Weisman, & Emery, 2007). It is worth 
mentioning that immunological treatments lead to disease remission in only 60% to 
70% of cases. Hence, much more needs to be understood concerning the underlying 
reasons of tissue destruction in order to improve treatment targeting and response 
(Smolen et al., 2016). 
Currently used biomarkers for RA, serum RF and serum ACPA, have been 
reported to exist several years before synovial manifestations in seropositive RA. 
However, these autoantibodies do not directly lead to disease generation, as they are 
also detected in healthy individuals (Rantapää-Dahlqvist et al., 2003). Hence,  ACPA 
and RF tend to lack sufficient sensitivity even though they both show relatively high 
specificity for RA. Notable, the production of RF is also common in autoimmune 
diseases in general (Nell, 2005). The specificity and sensitivity rate of ACPA and RF 
in predicting seropositive RA are, respectively, 95% and 67% for ACPA and 85% 
and 69% for RF, indicating that they can only be used for strengthening the 
estimation and not for exclusion (Nishimura et al., 2007). However, they have been 
reported to show prognostic value as RF and especially ACPA positivity is associated 
with more aggressive disease development and support early intensive treatment.(de 
Brito Rocha, Baldo, & Andrade, 2019). In addition to traditional antibodies, 
nonspecific inflammatory markers CRP and ESR are used in the diagnosis of RA, 
and they have a significant role in clinical decision-making when identifying patients 
with seronegative RA (Aletaha et al., 2010). 
In addition, new promising biomarkers for RA, such as anti-CarP and anti-PADs, 
were recently reported. Previous research demonstrated that serum anti-CarP 
antibodies have even higher specificity for RA than the traditional biomarkers and is 
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associated with more progressive RA. However, because of a poor sensitivity, anti-
CarP could potentially only be used as a prognostic biomarker for RA (Shi et al., 
2011; Spinelli et al., 2018). Likewise, determination of antibodies against PAD 
isoforms 2 (anti-PAD2) and 4 (anti-PAD4) together with antibodies against a 
subgroup of anti-PAD4 that cross-reacts with PAD3 (anti-PAD3/4), have been 
reported to show prognostic value in RA. More specifically, anti-PAD4 and anti-
PAD3/4 were associated with more severe RA (Giles et al., 2014; Halvorsen et al., 
2008) whereas anti-PAD2 was present in patients with milder symptoms and less 
progressive disease (Darrah et al., 2018). These findings suggest that RA have several 
phenotypes which differ in underlying disease pathophysiology. However, despite 
these promising results, questions remain and further studies are clearly needed to 
understand the relevance of the aforementioned antibodies in clinical field. In 
addition, according to current knowledge, anti-CarP and anti-PAD determinations 
would provide only limited advantage for RA diagnostics. 
A diagnosis of RA is based on symptoms, physical examination, laboratory tests 
and imaging. The 2010 EULAR/American College of Rheumatology (ACR) 
classification criteria for RA combines multiple predicting factors and can indicate 
the disease.  Fulfillment gives 82% sensitivity and 61% specificity meaning that the 
diagnosis can also be made in patients who do not meet all of the classification 
criteria. Therefore, the ultimate diagnosis of RA has to be made by a rheumatologist. 
The 2010 EULAR/ACR classification criteria for RA are presented in detail in Table 
5 (Aletaha et al., 2010). The included predicting factors are typical generation of RA-
specific symptoms, presence of acute-phase response, and production of 
autoantibodies APCA and RF. In later stages, CRP and ESR together with the 
development of symptoms are used to reflect the disease activity and efficacy of a 
given treatment. 
The fact that typical symptoms are often required for the diagnosis of RA is 
somewhat problematic, as the symptoms generally reflect an irreversible destruction 
of joints. In other words, patients cannot be detected and treated in a preventive 
way. The future goal for clinicians is to identify patients in the pre-RA stage in order 
to initiate efficient DMARD therapy and decrease functional disability. New details 
of the pathological processes could give rise to novel inventions in the field of 
diagnostics and DMARD therapy. 
  
 43 
 
Table 5. The 2010 EULAR/ACR classification criteria for RA.   
          Score 
Target population: (Who should be tested?) 
   
     (1) Patients who have at least one joint with definite clinical synovitis (swelling)a 
        (2) Patients with the synovitis not better explained by another diseaseb 
Classification criteria for RA (scoreǦbased algorithm: add score of categories A–D; a 
score of ≥6 out of 10 is needed for the classification of a patient as having definite RAc 
 
A. Joint involvementd:         
     1 large jointe       0 
     2 - 10 large joints       1 
     1–3 small joints (with or without the involvement of large joints)f 2 
     4–10 small joints (with or without the involvement of large joints) 3 
     >10 joints (at least one small joint)g     5 
B. Serology h: (At least one test result is needed for classification.) 
  
     Negative RF and negative ACPA 
  0 
     Low-positive RF or low-positive ACPA 
  2 
     High-positive RF or high-positive ACPA 
  3 
C. Acute-phase reactants i: (At least one test result is needed for classification.)   
     Normal CRP and normal ESR     0 
     Abnormal CRP or abnormal ESR     1 
D. Duration of symptomsj: 
    
     <6 weeks 
    0 
     ≥6 weeks         1 
Adapted from the European League Against Rheumatism/American College of Rheumatology criteria 
(Aletaha et al., 2002). 
a The criteria are aimed at classification of newly presenting patients. In addition, patients with erosive 
disease typical of RA with a history compatible with prior fulfillment of the 2010 criteria should be classified 
as having RA. Patients with longstanding disease, including those with inactive disease (with or without 
treatment) who, based on retrospectively available data, have previously fulfilled the 2010 criteria should 
be classified as having RA. 
 b Differential diagnoses vary among patients with different presentations, but may they include conditions 
such as SLE, psoriatic arthritis, and gout.  An expert rheumatologist should be consulted in case of unclear 
relevant differential diagnoses. 
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c Although patients with a score of <6/10 are not classifiable as having RA, their status can be reassessed 
and the criteria might be fulfilled cumulatively over time.  
d Joint involvement refers to any swollen or tender joint on examination, which may be confirmed by imaging 
evidence of synovitis. The distal interphalangeal, first carpometacarpal, and first metatarsophalangeal 
joints are excluded from assessment. Categories of joint distribution are classified according to the location 
and number of involved joints, with placement into the highest category possible on the basis of the pattern 
of joint involvement. 
e ”Large joints” refer to the shoulders, elbows, hips, knees, and ankles. 
f ”Small joints” refer to the metacarpophalangeal joints, proximal interphalangeal joints, second  through 
fifth metatarsophalangeal joints, thumb interphalangeal joints, and wrists. 
g In this category, at least one of the involved joints must be a small joint; the other joints can include any 
combination of large and additional small joints, as well as other joints not specifically listed elsewhere 
(e.g., temporomandibular, acromioclavicular, sternoclavicular). 
h “Negative” refers to international unit (IU) values that are less than or equal to the upper limit of   normal 
(ULN) for the laboratory and assay; “low-positive” refers to IU values that are higher than the ULN but less 
than or equal to three times the ULN for the laboratory and assay; “high-positive” refers to IU values that 
are greater than three times the ULN for the laboratory and assay. When RF information is only available 
as positive or negative, a positive result should be scored as low-positive for RF. 
i Normal or abnormal is determined by local laboratory standards. 
j The “duration of symptoms” refers to patients’ self-report of the duration of signs or symptoms of synovitis 
(e.g., pain, swelling and tenderness) of joints that are clinically involved at the time of assessment 
regardless of their treatment status. 
ACPA = anticitrullinated protein antibody; EULAR/ACR = European League Against Rheumatism/American 
College of Rheumatology; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; RA = 
rheumatoid arthritis; RF = rheumatoid factor 
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2.4 General features of proprotein convertases 
Many secreted proteins, enzymes and receptors are initially synthesized as inactive 
precursors that need to be proteolytically processed into biologically active forms. A 
comprehensive reservoir of various precursors enables a fast response to alterations 
in internal or external demands. Proprotein convertase subtilisin/kexin (PCSK) 
enzymes are responsible for the proteolytic conversion of dormant promolecules 
and hence dictate their bioavailability. Consequently, PCSKs are important 
regulatory factors in biology (Seidah et al., 2008). 
The PCSK protein family includes nine mammalian serine endoproteases 
possessing various biochemical activities. Similar to secretory proteins, PCSKs are 
initially produced as inactive zymogens and undergo a series of pH- and Ca2+-
dependent autoproteolytic events to become enzymatically active (Seidah et al., 
2008). The initially identified seven PCSKs (PCSK1–2, Furin, and PCSK4–7) 
originate from bacterial subtilases and yeast kexin and resemble each other in 
structure and biochemical features (Thomas, 2002). These conventional PCSKs are 
localized primarily in the secretory pathway, in endosomes, and on the cell surface. 
All of them cleave after C-terminal, single or paired basic amino acid lysine (K), 
and/or arginine (R) motif (K/R) – (X)n – (K/R) ↓, where n = 0, 2, 4, or 6 and X = 
any amino acid, except Cys, ↓ = the site of proteolysis (Hipp et al., 2013; Turpeinen, 
Ortutay, & Pesu, 2013). In vitro experiments suggest that the conventional PCSKs 
exhibit closely related, or even complementary, biochemical functions. However, 
studies with genetically engineered animal models indicate substrate specificity, 
which leaves fundamental relations of individual PCSKs contradictory (Thomas, 
2002). 
PCSK1 and PCSK2 are predominantly expressed in endocrine and 
neuroendocrine cells and participate in the regulation of sugar metabolisms by 
cleaving proinsulin and proglucagon (Day et al., 1992; Hipp et al., 2013; Roebroek 
et al., 1998). Overlap in the PCSK1 and PCSK2 expression patterns leads to shared 
substrates. However, the final outcomes can differ remarkably, as enzymes differ in 
proteolytic functions and cleave the same substrates in distinct manners (Turpeinen 
et al., 2013). PCSK4 is predominantly expressed in reproductive organs, exclusively 
in ovarian and testicular tissues, and its dysregulation is associated with infertility 
(Hipp et al., 2013; Roebroek et al., 1998). Furin and PCSK 5–6 are ubiquitously 
expressed and mandatory factors in embryogenesis. Hence, investigations are limited 
to in vivo experiments, and their fundamental cell-specific functions remain unclear 
(Thomas, 2002). PCSK7 is also ubiquitously expressed and has previously been 
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suggested to have a role in regulating iron homeostasis (Oexle et al., 2011). Notably, 
the last two PCSK enzymes differ greatly from the first seven conventional PCSKs, 
as they are highly associated with lipid metabolism. More specifically, PCSK8 has 
been shown to be involved in cholesterol metabolism by increasing the cholesterol 
and fatty acid synthesis, whereas PCSK9 specifically regulates the low-density 
lipoprotein (LDL) levels of serum by targeting the LDL receptors on hepatocytes 
for endosomal degradation (Turpeinen et al., 2011). 
The changes in PCSK expression and activity are also important factors in human 
diseases. Some conventional PCSK enzymes, such as Furin and PCSK6, promote 
the malignant behavior of solid tumors (Bassi, Mahloogi, & Klein-Szanto, 2000). For 
example, Furin is upregulated in non-small cell lung carcinomas as well as in human 
head and neck squamous cell carcinomas, and the elevated Furin activity correlates 
positively with accelerated tumor progression (Fu, Bassi, Zhang, Li, Nicolas, & 
Klein-Szanto, 2015). An elevated PCSK expression also enhances the proteolytic 
pathogen activation. For example, genetic association studies show that a single 
nucleotide polymorphism on the promoter of FUR gene regulates Furin levels, 
which affects the replication of hepatitis B virus (Lei et al., 2009). Similarly, Furin 
processes exotoxin A secreted by Pseudomonas aeruginosa and consequently 
worsens the outcome of cystic fibrosis (Ornatowski, Poschet, Perkett, Taylor-
Cousar, & Deretic, 2007). 
A large genome-wide association study on blood pressure demonstrated a 
significant association between Furin–Fes locus and an elevated risk for 
cardiovascular disease (Ganesh et al., 2013). Therefore, agents that either promote 
or prevent PCSK function can be beneficial in the treatment of a variety of human 
diseases. For example, the US Food and Drug Administration approved the use of 
PCSK9-blocking agents (Evolocumab and Alirocumab) for the treatment of 
resistant hypercholesterolemia in the United States in 2015 (Chaudhary, Garg, Shah, 
& Sumner, 2017). Because PCSKs play a critical role in disease pathogenesis, they 
might have a potential value as future biomarkers in facilitating diagnostics of these 
diseases.  Table 6 summarizes the associations between gene polymorphisms of the 
nine PCSK enzymes and human traits and diseases. 
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Table 6. Associations between PCSK gene polymorphisms and human traits and diseases. 
            
PCSK gene   Human disease/traits association     
PCSK1   Obesity       
    Glucose homeostasis      
    Proinsulin levels      
PCSK2  Myocardial infarction   
  Chronic kidney diseases   
  Glucose homeostasis    
FUR   Hypertension       
    Outcome of HBV infection     
    Aggressive tumor progression     
PCSK4  Not studied    
      
      
PCSK5   Neurodegenerative diseases     
    HDL levels       
            
PCSK6  Blood pressure    
  Handedness in dyslexia   
      
PCSK7   Iron homeostasis      
    Cholesterol and lipid metabolism      
            
PCSK8  Cholesterol and lipid metabolism    
      
      
PCSK9   Cholesterol and lipid metabolism      
            
            
Adapted from genome-wide association studies (Artenstein & Opal, 2011; Turpeinen et al., 
2013).  HBV = hepatitis B virus; HDL = high-density lipoprotein; PCSK = proprotein convertase 
subtilisin/kexin. 
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2.5 Biology of Furin (PCSK3) 
Furin is the first found, and hence the most studied, mammalian proprotein 
convertase. It is encoded by the human C-FES/FPS proto-oncogene on 
chromosome 15q26.1 (Jhanwar, Neel, Hayward, & Chaganti, 1984; Roebroek et al., 
1986). It is localized in the upstream region of FES and is, hence, also referred to as 
FUR (FES upstream region) gene (Roebroek et al., 1986). The novel proprotein 
convertase enzyme was named Furin after its encoding gene. It is expressed in all 
tissues and is located mostly in the trans-Golgi network in the secretory pathway. In 
addition, it cycles between the Golgi apparatus and the cell surface via the endosomal 
system (Shiryaev et al., 2007; Thomas, 2002). Furin is first produced as an immature 
proenzyme and has to be activated through a two-step pH- and Ca2+-dependent 
autoactivation. The first cleavage occurs in the neutral pH of the endoplasmic 
reticulum, and the second calcium-dependent cleavage is located in the more acidic 
environment in the Golgi apparatus. From there, it is sent to its target position (Hipp 
et al., 2013). Because of the wide Furin expression, its activity affects the maturation 
of numerous precursor proteins. Furin substrates include, for example, growth 
factors and their receptors, enzymes, hormones, cytokines, serum proteins, 
neutrophil factors, extracellular matrix proteins, and infectious agents (Thomas, 
2002; Turpeinen et al., 2013). Hence, Furin is important in regulating general 
homeostasis. 
Previous studies suggest that Furin is also involved in the pathogenesis of several 
diseases. For example, elevated Furin levels have been associated with aggressive 
cancers and metastasis (Fu et al., 2015). In addition, studies indicate that it is a 
significant factor in the initiation of a microbial infection. It promotes pathogen 
invasion by cleaving viruses’ membrane proteins and the inhibiting sequences of 
bacterial protoxins (Shiryaev et al., 2007).  
2.5.1 Furin in regulating the immune system 
Previous studies have demonstrated the key regulatory role of Furin in both adaptive 
and innate immune responses. It is predominantly expressed in TH1 cells and 
induced via the IL-12/STAT4 pathway and TCR-mediated signaling (Pesu, Muul, 
Kanno, & O’Shea, 2006). Moreover, the genome-wide expression quantitative trait 
loci (eQTL) analysis of Furin expression in peripheral blood (PB) demonstrated that, 
 49 
 
besides extracellular signaling, Furin is also regulated genetically (Turpeinen et al., 
2015).  
Macrophage and T cell activation promotes Furin upregulation during an acute 
infection (Hipp et al., 2013; Turpeinen et al., 2011). In addition, LPS stimulates Furin 
expression in macrophages. Upregulated Furin promotes immune response by 
enhancing TLR7 and TLR9 receptor processing and stimulating IFN-γ secretion in 
activated TH1 cells (Hipp et al., 2013; Pesu et al., 2006; Turpeinen et al., 2011).  An 
elevated Furin levels has been reported, for example, in serum of patients with 
chronic Salmonella typhi–infection Furin has also been shown to be upregulated in 
lymphocytes and macrophages isolated from atherosclerotic plaques, indicating its 
potential role in the maintenance of chronic inflammation (Turpeinen et al., 2011). 
On the contrary, it has anti-inflammatory effects in LysM+ myeloid cells 
(macrophages and granulocytes) where it restrains the production of 
proinflammatory cytokines (Cordova et al., 2016). As a conclusion, relatively little is 
known about the fundamental role of Furin in human infections. 
T-cell-expressed Furin also has an essential role in maintaining peripheral 
tolerance. It regulates TH1/TH2-cell-type polarization and functional maturity of the 
anti-inflammatory cytokine TGF-β1 (Oksanen et al., 2014; Pesu et al., 2006, Pesu et 
al., 2008;). TGF-β1, in turn, is found to be essential in the development of FoxP3+ 
Treg cells (Haribhai et al., 2016). It also regulates Furin expression via a negative 
feedback loop (Blanchette, Day, Dong, Laprise, & Dubois, 1997). The key role of 
Furin in immunological tolerance has been demonstrated in the conventional 
knockout animal studies where T-cell-specific Furin knockout mice develop age-
related systemic autoimmunity characterized by the clonal expansion of CD4+ and 
CD8+ T cells, excessive production of proinflammatory cytokines, and lack of 
functional FoxP3+ Treg cells as a result of defective pro-TGF-β1 processing (Pesu 
et al., 2008). Figure 2 summarizes the main actions of Furin in regulating the immune 
system. 
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Figure 2.  The role of Furin in regulating the immune system.  Mature DCs migrate to secondary 
lymphatic organs to present antigens and activate naive T cells. Activated CD4+ T cells 
polarize into different subgroups on the basis of presented cytokine environment. Furin is 
predominantly expressed in TH1 cells via IL-12/STAT4 mediated pathway. Furin expression 
in TH1 cells inhibit TH2 polarization by downregulating IL-4Rα expression on the cell surface 
of pre-TH2 cells. Hence, Furin has an important role in the regulation of TH1/ TH2 balance. 
Moreover, T-cell-expressed Furin is also responsible for the functional maturation of pro-
TGF-β1 and is therefore essential in the maintenance of peripheral immune tolerance. The 
figure is based on Oksanen et al., 2014; Pesu et al., 2006; and Pesu et al., 2008. 
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3 AIMS OF THE STUDY 
Immune-mediated diseases (IMDs) are a result of a dysregulated immune system. 
Still little is known about the fundamental reasons for the pathogenesis of IMDs, 
which makes their accurate prevention, detection, and treatment a challenge. As a 
result, irreversible damage and lost abilities are far often present at the time of 
diagnosis. Hence, better tools for a timely and accurate diagnostics of IMDs are 
urgently needed. The PCSK enzyme Furin has a key regulatory role in both innate 
and adaptive immune responses. Previous studies have shown altered Furin 
expressions in various inflammatory conditions, including the development of 
metastatic cancer, infectious diseases, and atherosclerosis. However, studies to date 
have not yet investigated the usability of Furin measurements in clinical practice in 
IMDs.   
The detailed objectives of the study are as follows: 
(1) To investigate the clinical relevance of plasma Furin measurements in 
diagnostics, prognosis, and follow-up of acute infection, pSS, and RA 
 
(2) To examine the usability of Furin messenger ribonucleic acid (mRNA) 
measurements in assessing clinical and immunological characteristics in pSS 
and RA 
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4 PATIENTS AND METHODS 
4.1 Study population and human samples (I–III) 
4.1.1 Study I—patients with suspected infection 
Data for the first study was collected from the emergency department of Satakunta 
Central Hospital in Finland between the years 2004 and 2005. Satakunta Central 
Hospital is a secondary care unit with 350 beds and it provides first-aid services and 
intensive care for around 240 000 people in Satakunta district. Primary inclusion 
criteria for the study were admission to the emergency room, symptoms or clinical 
findings indicating an infectious disease and a medical indication for blood culture 
samples. Noteworthy, only patients aged 18 or more were accepted in the study. 
Comprehensive matching between the study and general population was assessed 
using a pre-evaluation that comprised demographic data from 1551 control patients. 
The control group consisted of consecutive first-aid patients with blood culture 
sample who had been previously admitted to the emergency room of Satakunta 
Central Hospital. No significant differences in age, gender, mortality or the rate of 
positive blood cultures between the two groups was obtained (Uusitalo-Seppälä et 
al., 2013). 
The collected data consisted of plasma samples, reports from structured 
interviews, clinical data from days of hospitalization, medical history, and a follow-
up survey. In total, 609 plasma samples were collected during the 14-month study 
period. They were obtained simultaneously with other blood samples and collected 
in two 10-ml ethylenediaminetetraacetic acid (EDTA) tubes that were preserved in 
ice before further processing. The samples were centrifuged in 2500 g force for 10 
to 15 minutes and then shifted carefully in 1- to 2-ml aliquots to CryoPure tubes 
(Sartsedt, Germany) and stored at –70°C. Written consent of participation was 
required from the patients or, alternatively, their close relatives. As a result, 55 
patients had to be excluded from further investigations. Structured interviews 
concerning symptoms and medical history were conducted 24 to 48 hours after 
admission. To ensure the fulfillment of a strict timeline, only patients admitted 
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between Sunday 7 a.m. and Wednesday 3 p.m. were included in the study. 
Comprehensive clinical data were gathered during hospitalization, which included 
daily observations of the highest body temperature, lowest blood pressure, highest 
pulse, and respiratory rates from the first 7 days of treatment. In addition, the 
underlying diseases, potential causes of infection, primary symptoms and clinical 
findings, first and final diagnosis, common risk factors for sepsis and organ failures 
(heart, circulation, liver, kidneys, lungs, and brain), case fatality, and sepsis-mediated 
case fatality were collected from medical records. Three-month and one-year follow-
up checks were conducted by making phone calls. 
Eventually, 17 plasma samples were excluded from the study because of the 
following reasons: 11 unclear results, 3 suggesting SIRS and MOF but no bacterial 
infection, 2 insufficient size, and 1 missing. Consequently, the final data consisted of 
537 first-aid patients. These data have previously been used in other studies 
(Uusitalo-Sepplälä et al., 2011; Uusitalo-Seppälä et al., 2012; Uusitalo-Seppälä et al., 
2013; Uusitalo-Seppälä, Peuravuori, Koskinen, Vahlberg, & Rintala, 2012). 
The ACCP/SCCM Consensus Committee definitions were used for dividing 
patients into five diagnostic groups with respect to disease severity in order to assess 
associations between Furin plasma levels and clinical manifestations (Bone et al., 
1992). 
4.1.2 Study II—patients with pSS 
Participants in the second study were recruited from the Centre for Rheumatic 
Diseases in Tampere University Hospital, Finland. In total, 16 patients with the 
active state of pSS were enrolled. Detailed inclusion criteria covered the fulfillment 
of four or more revised American–European consensus group criteria for pSS and 
a verification of systemic disease activity with either ESSDAI score >11 or 
laboratory test results: ESR >20 mm/h, IgG >15 g/L, serum β2-microglobulin >2.2 
mg/L, or serum complement C4 <0.10 g/L (Vitali, 2002).  The final group consisted 
of 14 female and 2 male patients, with a median age of 53 years (range 32–80 years), 
disease duration of 11 years (range 0–27 years), and disease activity index (ESSDAI) 
of 5.00 (interquartile range 3.00–8.75). Five patients were treated with 
immunosuppressive medications at the time of sampling. 
PB samples were collected into BD Vacutainer tubes (BD Biosciences, San Jose, 
CA, USA) containing acid citrate dextrose (ACD) solution B as an anticoagulant and 
were stored at −70°C. Furthermore, 10 peripheral blood mononuclear cell (PBMC) 
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samples and 14 control plasma samples were drawn randomly from the pool of 
healthy blood donors (Finnish Red Cross Blood Transfusion Service, Tampere, 
Finland). Clinical and laboratory data of patients with pSS were gathered from the 
patients’ records. The data have been used in previous publications (Pertovaara, 
Silvennoinen, & Isomäki, 2015; Pertovaara, Silvennoinen, & Isomäki, 2016). 
4.1.3 Study III—patients with RA 
Participants in the third study were recruited from the Centre for Rheumatic 
Diseases in Tampere University Hospital. The predominant criterion for inclusion 
was the diagnosis of an active RA. In accordance with scientific principles, written 
consent was obtained from every participant. The total data for the study comprised 
17 plasma samples, 16 PBMC samples, 8 synovial fluid mononuclear cell (SFMC) 
samples, and 8 sets of purified T cells and monocytes obtained from patients with 
RA. Control samples were gathered from anonymous healthy blood donors (Finnish 
Red Cross Blood Transfusion Service). 
Clinical and demographic characteristics of the patient groups were as follows: 
The plasma sample group consisted of 4 men and 13 women, with a median age of 
66 years (range 52–88 years), median disease duration of 7 years (range 0–29 years), 
median CRP of 18 mg/L (range 0–68 g/L), and median ESR of 40 mm/h (range 7–
118 mm/h). The PBMC sample group consisted of 7 men and 9 women, with a 
median age of 66 years (range 32–88 years), median disease duration of 15 years 
(range 0–37 years), median CRP of 30 mg/L (range 11–114 g/L), and median ESR 
of 42 mm/h (range 10–118 mm/h). The SFMC sample group consisted of 6 men 
and 2 women, with a median age of 54 years (range 32–72 years), median disease 
duration of 11 years (range 1–37 years), median CRP of 44 mg/L (range 15–114 
g/L), and median ESR of 32 mm/h (range 10–88 mm/h). The purified T cells and 
monocytes group consisted of 8 patients, with a median age of 62 years (range 37–
87 years), median disease duration of 18.5 years (range 0.25–49.0 years), median CRP 
of 25 mg/L (range 18–67 mg/L), and median ESR of 36 mm/h (range 10–91 
mm/h). Previous and current use of immunosuppressive treatment was allowed in 
every patient group. 
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4.2 Measurement of Furin plasma levels (I–III) 
The measurements of serum Furin levels were carried out using a commercial 
Human Furin ELISA (enzyme-linked immunosorbent assay) Kit according to the 
manufacturer’s instructions in all three studies (Sigma-Aldrich, USA (I and II) or 
Thermo Scientific, USA (III)). In study I, samples showing exceptionally high 
protein levels were analyzed again using higher dilution, and for studies II and III, 
duplicated analyses were performed for every sample to ensure reliable results. The 
detection limit of ELISA varied between patient groups as follows: 370 pg/ml for 
first-aid patients (I) and 123 pg/ml for patients with pSS or RA (II and III). All 
concentrations less than this were considered to represent low (I and III) or absent 
(II) protein levels. For all studies, the patients were further stratified into low- and 
high-plasma Furin groups in accordance with detection threshold (370 pg/ml for 
study I and 123 pg/ml for study III) or median plasma Furin concentration (2690 
pg/ml for study II). 
4.3 Cell purification (II and III) 
To study Furin mRNA expression in pSS in study II, PBMCs were isolated from 
blood samples using Ficoll-Paque Plus (Amersham Biosciences, Buckinghamshire, 
UK) density gradient centrifugation. Respectively, examinations of the FUR gene 
expression in patients with RA in study III followed an identical protocol, except 
that SFMCs were isolated from synovial fluid samples. 
For study III, additional T cells and monocytes were isolated from eight patients 
with RA, using magnetic beds (Miltenyi Biotec, Auburn, CA, USA; III) and 
sequential negative selection (Pan T Cell Isolation Kit; Miltenyi Biotec) for T cells 
and positive selection with anti-CD14-coated microbeads for monocytes. The 
ribonucleic acid (RNA) from purified cells was further extracted for quantitative real-
time polymerase chain reaction (Q-RT-PCR) experiments (II–III). 
4.4 Q-RT-PCR (II and III) 
In study II, the total RNA from human PBMCs was isolated using the RNeasy Mini 
Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions and 
reverse transcribed into complementary deoxyribonucleic acid (cDNA) with Maxima 
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Reverse Transcriptase and random hexamers (Thermo Scientific, Waltham, MA, 
USA). An identical protocol was followed when isolating the total RNA from human 
PBMCs and SFMCs for study III. 
The Primer3 software (available at http://primer3.sourceforge.net) was used to 
design forward and reverse primers for Furin and TATA-binding protein (TBP, 
housekeeping) for studies II and III. The following primer sequences were used: 5'-
GGCAAAGCGACGGACTAAAC-3' and 5'-CGTCCAGAATGGAGACCACA-3' 
for Furin, and 5'-GAATATAATCCCAAGCGGTTTG-3' and 5'-
ACTTCACATCACAGCTCCCC-3' for TBP (Pertovaara et al., 2015). Q-RT-PCR 
analyses were performed using a CFX96 instrument together with Maxima SYBR 
Green/ROX (Thermo Scientific) master. TBP was used for normalization of the 
Furin expression in both studies (II and III) in order to minimize errors in sample 
quantifications. The relative Furin expression was calculated by dividing the mean 
expression level of Furin by the mean expression of the TBP obtained from 
triplicated samples. 
4.5 Statistical analyses (I–III) 
Data management and analysis were performed using SPSS version 22.0 (IBM 
Corp., Armonk, NY, USA) in studies I and III and version 20.0 in study II. Statistical 
significance was calculated using different analyses depending on the variable type, 
distribution, and sample size. In study I, Student’s t-test and analysis of variance were 
used for normally distributed variables, and the Mann–Whitney U-test and Kruskal–
Wallis test were used to evaluate the statistical significance of variables from non-
Gaussian population data. Chi-squared and Fisher’s exact test were used in assessing 
the statistical significance between binomial variables. Regression analysis was used 
for investigating the effects of potential confounders. The fatality in different Furin 
plasma levels was assessed using the log-rank (Kaplan–Meier) test. 
The nonparametric Mann–Whitney U-test was used to determine the statistical 
differences in patients with pSS (II) and RA (III). In addition, Fisher’s exact test was 
used in Furin mRNA expression analyses in study III in terms of analyzing sample 
sizes less than n = 50. Spearman’s correlation coefficient was used to determine the 
associations between gene expression level and clinical and demographic parameters 
(II–III). 
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Common significance levels were used in all analyses: p-values < 0.05 were 
considered statistically significant, and p-values < 0.001 indicated a high statistical 
significance (I–III). 
4.6 Ethical considerations (I–III) 
The collection of human plasma samples and their use in studying infectious diseases 
were approved by the Ethics Committee of Satakunta Central Hospital (I). 
Correspondingly, the permission to collect blood and synovial fluid samples from 
patients with pSS (II) and RA (III) together with their use in examining the 
pathogenesis of rheumatic diseases was given by the Ethics Committee of Tampere 
University Hospital. New patient samples or patient data were not collected during 
the presented studies. All patients were comprehensively informed about the use of 
collected samples and their personal medical records in the following clinical trials. 
In every study (I–III), written consent was required from either the participants or 
their close relatives. Stored personal data were processed and described by research 
numbers to achieve anonymity and protect patients’ privacy.  
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5 SUMMARY OF THE RESULTS 
5.1  Furin plasma level as biomarker for suspected infection (I) 
In study I, ELISA measurements were used as described in Section 4 to analyze the 
Furin plasma levels from 537 first-aid patients admitted to the ER, with clinical signs 
suggesting infectious diseases. In addition, medical history, demographic 
characteristics, and infection-associated clinical parameters for the time of 
hospitalization and results from two follow-up surveys were collected to investigate 
the associations between initial Furin plasma levels and disease outcomes. Follow-
up surveys were conducted 3 months and 1 year after the initial admission to the ER. 
In addition, we assessed the utility of Furin plasma measurements in diagnosis and 
initial treatment selection for the early phase of infection. 
In particular, Furin ELISA measurements turned out to be technically 
problematic. Concentrations less than 370 pg/ml could not be reliably detected, and 
hence, the patients were further classified into high- and low-level Furin groups, with 
a cutoff level at the detection threshold. Further, the patients were divided into five 
diagnostic groups according to their clinical findings and symptom severity on the 
basis of the ACCP/SCCM Consensus Committee definitions: group 1, no SIRS or 
bacterial infection (n = 59 patients); group 2, bacterial infection without SIRS (n = 
67); group 3, SIRS without bacterial infection (n = 308); group 4, sepsis without 
organ failure (n = 308); and group 5, sepsis and organ failure (n = 49; The presence 
of high Furin plasma levels varied from 14.9% to 22.0% among these five diagnostic 
groups. Low Furin plasma levels were concentrated in group 2, whereas group 1 
showed most predominantly high Furin plasma levels, suggesting that Furin might 
have a role in preventing pathogen invasion. However, no significant correlation was 
found among the different groups and the Furin plasma levels (p = 0.737). 
Next, we investigated if Furin plasma measurements could be beneficial in 
predicting changes in general infection-associated clinical parameters by assessing 
their correlations with the groups of patients with high- and low-level Furin. We also 
studied the connections between Furin plasma level and underlying diseases, as well 
as demographic characteristics, to discover potential risk factors for distinct Furin 
expression. Despite the fact that an increased Furin expression has been 
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demonstrated in atherosclerotic plaques and malignancies (Li et al., 2010; Thomas, 
2002; Turpeinen et al., 2011), no evidence of correlation between the prevalence of 
solid cancer (p = 0.606) or cardiovascular diseases (p = 0.204) was found in patient 
groups. However, consistent with earlier studies demonstrating Furin upregulation 
in the synovial pannus of patients with RA (Lin et al., 2012), an elevated Furin plasma 
level was observed to correlate strongly with the presence of rheumatic diseases (p 
<0.001). Interestingly, in contrast to 7.0% representation of rheumatic diseases in 
the low-level Furin group, even 18.5% of patients expressing high Furin plasma 
levels had a previous diagnosis of rheumatic diseases. On the contrary, 40% of 
patients with underlying RA presented high Furin plasma compared to 18% in the 
patient group with no history of rheumatic diseases. We also noted a surprising 
connection between current smoking and a tendency for expressing low Furin 
plasma levels (p = 0.034). Taken together, these results suggest that Furin plasma 
levels at least when determined with the used ELISA measurements cannot be used 
as a diagnostic biomarker for first-aid patients with suspected infection. 
The next section of study I evaluated the potential use of Furin as a prognostic 
marker for ER patients with infectious manifestations. However, the analysis 
showed no significant differences between Furin plasma levels and development of 
sepsis (p = 0.957), multiorgan failure (p = 0.421), or any of the other clinical 
manifestations during the first 28 days of hospitalization. Furin expression was not 
found to be associated with 28-day case fatality among patients who died or 
developed severe illness as a result of the sepsis syndrome (p = 0.463). Next, two 
survival curves were constructed to further investigate the predicting value of Furin 
plasma levels in disease severity. Because Furin is unregulated in activated T cells 
(Pesu et al., 2006) and dysregulation of T cell response appears to play a pivotal role 
in developing sepsis (Yang, 2014), we targeted our survival analysis to patients who 
were initially diagnosed with sepsis (groups 4 and 5). Because sepsis-related deaths 
tend to occur during the first month, the analysis was focused on the first 28 days of 
treatment. The presence of any other direct causes of deaths during the determined 
time limit resulted in exclusion from the analysis (n = 13). However, no evidence of 
significant association between the initial Furin plasma level and the case fatality of 
patients with sepsis was found (p = 0.898). The data did not show a significant 
difference between Furin levels and case fatality during 1-year follow-up surveys (p 
= 0.742). 
Lastly, we assessed the potential value of Furin plasma measurements in the 
initiation of empiric antimicrobial treatment. The patients were divided into four 
groups in accordance with blood culture findings to analyze the potential differences 
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in Furin expressions. These were as follows: no growth (n = 485), gram-positive 
finding (n = 28), gram-negative finding (n = 16), and mixed infection (n = 7). Because 
LPSs have been shown to induce Furin expression in macrophages (Kumar et al., 
2014; Meissner, Scheltema, Mollenkopf, & Mann et al., 2013), we expected to see 
differences between dissimilar microbial infections. However, no significant 
difference in these four groups was evident (p = 0.351). Next, we determined the 
distribution of Furin concentration groups between gram-positive and -negative 
bacterial growth and also between single bacterial species separately. Gram-negative 
Escherichia coli (n = 11) and gram-positive Streptococcus pneumoniae (n = 10) were the 
most common causes of bacteremia in our study group. In parallel to previous 
analyses, none of the differences concerning Furin plasma measurements and 
individual bacterial species were statistically significant. These results suggest that 
Furin plasma measurements cannot be used in decision-making of the initial 
antimicrobial treatment.  
In summary, the used ELISA measurements of Furin plasma level cannot be used 
as a biomarker for first-aid patients with suspected infection. In more detail, the 
Furin plasma level did not predict blood culture results, disease severity, diagnostic 
group, or case fatality. However, because high Furin levels appeared to associate with 
underlying rheumatic diseases, Furin could potentially have a better value as a 
biomarker for autoimmune diseases. 
5.2 Furin as biomarker for pSS (II) 
Because study I showed an interesting correlation between Furin plasma levels and 
rheumatic diseases, we next assessed the potential usability of Furin measurements 
as a biomarker for autoimmune diseases. In study II, we focused on determining 
Furin expression levels in patients with pSS to evaluate whether or not they could 
be used to facilitate diagnostics and clinical decision-making in this study group. In 
addition, the associations between Furin expression levels and clinical and 
demographic characteristics of patients were assessed to detect any causal 
relationships. Because of the problematic use of ELISA in study I, we broadened 
our method repertoire to also cover Furin mRNA measurements from isolated 
PBMCs, using the Q-RT-PCR method. We also changed the manufacturer of the 
ELISA Kit for this study. Nonetheless, similar detection deficiency of the ELISA 
Kit was once again faced. The reliable detection limit of new ELISA in study II was 
123 pg/ml, and all samples with a concentration less than this threshold were 
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considered to have the absence of the protein. The Furin plasma levels were 
compared between patients with pSS and healthy controls to evaluate whether or 
not Furin was elevated in pSS. Our results showed that Furin was significantly higher 
in patients with pSS compared to healthy controls (median 0 vs. 2690 pg/ml; p = 
0.0181). Next, we compared the Furin mRNA expression in PBMCs between 
patients and controls in order to estimate if the detected elevation was caused by 
speeding up the protein secretion or by increase in gene expression. Furin mRNA 
expression in isolated PBMCs was found to be significantly higher in patients with 
pSS (p = 0.0061), indicating that the FUR gene is upregulated in patients with pSS. 
This finding is consistent with the earlier findings considering Furin measurements 
from plasma samples. 
In the second section of study II, we investigated whether or not the elevation in 
Furin plasma levels was associated with demographic, clinical, or disease-associated 
immunological features of patients with pSS. The patient group was divided into a 
high- and low-level Furin groups because of the insensitive detection of Furin levels 
less than 123 pg/ml. The median Furin concentration was 2690 pg/ml, and it was 
used as a cutoff level for the two concentration groups. On average, patients with 
high Furin plasma levels were also reported to have significantly longer duration of 
the symptoms of dry eye than those showing low Furin concentrations (median 13 
years vs. 9 years; p = 0.035). In addition, they had significantly elevated IFN-γ levels 
(median 100.0 pg/ml vs. 27.2 pg/ml; p = 0.036). The correlations between Furin 
plasma levels and IFN-γ levels (Spearman’s correlation, r = 0.631; p = 0.009) and 
with the duration of the symptoms of dry eye (r = 0.520; p = 0.038) were confirmed 
to be statistically significant in subsequent analyses. No other statistically significant 
difference between patients’ characteristics and Furin plasma concentration was 
detected. However, there was an interesting trend for lower serum β2-microglobulin 
level (median 2.30 mg/L vs. 3.05 mg/L; p = 0.050), ESR (median 11 mm/h vs. 29 
mm/h; p = 0.138), and systemic disease activity index ESSDAI (median 3.00 vs. 6.50; 
p = 0.205) in patients with pSS having high Furin levels compared to the low-level 
Furin group. 
When taken together, our results demonstrated that the proprotein convertase 
Furin is significantly upregulated in pSS at both protein and mRNA levels and there 
was a significant association between high Furin levels and longer duration of the 
symptoms of dry eye and plasma IFN-γ levels. Contradictory, high Furin levels in 
plasma also tend to associate with smaller scores of disease activity indicators 
including beta-2 microglobulin, ESR and the systemic activity index ESSDAI, 
although this did not reach the statistical significance level.  
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5.3 Furin as biomarker for RA (III) 
Because both of our previous studies showed significant associations between 
elevated Furin levels and rheumatic diseases, suggesting its potential role in the 
pathogenesis, we wanted to perform further examinations concerning Furin 
expression in autoimmune diseases. We assessed Furin expressions in patients with 
RA, as it is one of the most common autoimmune diseases worldwide. We also 
investigated the potential utility of Furin measurements as a biomarker for RA by 
evaluating results’ associations with the common RA-associated clinical features. 
Similar ELISA measurements as in the study on pSS were used for determining 
the Furin plasma level from 17 patients with active RA. The reliable detection limit 
for ELISA was 123 pg/ml, and concentrations less than this were marked as 0 
pg/ml. In contrast to our previous studies of Furin in plasma, no statistically 
significant increase was detected when comparing patients with RA to healthy 
controls (p = 0.23). In fact, a high variability of Furin plasma levels was demonstrated 
in both groups. Nevertheless, there were higher detected Furin plasma levels among 
patients with RA (10 out of 17, 59%) compared to healthy controls (5 out of 14, 
35%). 
Next, the Furin mRNA expression level in isolated PBMCs was assessed from 
patients with active RA and healthy controls, using the Q-RT-PCR method. 
Statistical analysis showed that Furin mRNA expression in purified PBMCs from 
patients with RA showed significantly higher levels than did the control group (p < 
0.001). Furthermore, T cells (n = 7) and monocytes (n = 6) from the PB samples of 
patients with RA and healthy controls were further purified to investigate Furin 
mRNA expressions between distinct PBMC types. Our results demonstrated 
significantly higher Furin mRNA levels in PB T cells (p < 0.05) as well as PB 
monocytes (p < 0.01) in patients with RA compared to healthy controls. Moreover, 
Furin mRNA upregulation was higher in PB monocytes compared to PB T cells in 
examined samples from patients with RA. Because examinations of isolated PBMCs 
reflect mainly systemic effects, mononuclear cells were also isolated straight from 
synovial fluid in order to get better insights into the local alterations. Synovial fluid 
samples were taken from inflamed knee joints of eight patients with active RA. SF 
T cells (n = 4) and SF monocytes (n = 4) were purified from extracted SFMCs, using 
similar methods as described earlier with PBMCs. The detected Furin mRNA 
expression was in parallel with the analysis considering PB cells. The finding suggests 
a consistency in systemic and local changes in transcription of the FUR gene in the 
presence of active RA. In summary, although there was no significant difference in 
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Furin plasma levels between patients with RA and healthy controls, Furin was found 
to be highly significantly upregulated in RA at mRNA levels in both PB and SF 
mononuclear cells. 
The next section of study III evaluated the associations between Furin levels and 
characteristics of patients with active RA. First, we investigated whether or not Furin 
plasma was related to demographic or clinical features of patients with RA. Patients 
having detectable Furin levels had significantly higher doses of prednisolone (p = 
0.023) and a greater Health Assessment Questionnaire (HAQ) disability index (p = 
0.003) compared to those with lower Furin concentrations. Moreover, additional 
cytokine levels (IL-1β, IL-2, IL-4, IL-6, IL-7, IL-10, IFN-γ, and TNF-α) were 
determined from 10 plasma samples of patients with RA to evaluate their association 
with Furin plasma concentrations. Our analysis showed that patients expressing 
detectable Furin levels (7 out of 10) also demonstrated higher median levels of all 
evaluated cytokines when compared to those with low Furin plasma levels (3 out of 
10). However, differences concerning only IL-2 levels were found to be statistically 
significant (median 28 pg/ml vs. 6 pg/ml; p = 0.033). 
Second, we assessed if upregulated Furin mRNA would associate with clinical or 
demographic characteristics of patients with RA, using a similar protocol as earlier. 
A significant positive correlation was found between high Furin mRNA expression 
in PBMCs and current use (p = 0.020) and dose (p = 0.004) of prednisolone. In turn, 
patients with high Furin mRNA expression in SFMCs showed significantly higher 
acute-phase CRP levels (p < 0.001). In addition, there was a trend toward higher 
ESR level (r = 0.6667; p = 0.0710) and a higher prednisolone dose (r = 0.6747; p = 
0.0664) in patients with RA having higher Furin mRNA expression in SFMCs. 
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6 DISCUSSION 
6.1 Furin in suspected infection  
Infectious diseases are common problems in patients admitted to the ER. Although 
most of the conditions turn out to be harmless, dysfunctions in the regulation 
mechanisms of host defense can lead to life-threatening outcomes. The failure of 
suppressor functions leads to uncontrolled inflammation, which is associated with 
severe self-tissue damage and organ failures. Sepsis is defined as a condition with 
infection-related acute organ dysfunctions (Cecconi et al., 2018). It is considered a 
significant global health issue because it affects all age groups and is associated with 
a high risk of death. (Fleischmann et al., 2016). It is important to note that 
characteristic organ dysfunctions progress relatively fast, hence making urgent 
diagnosis vital. Consequently, even a short delay in the diagnosis and initiation of 
antimicrobial treatment is related to increased mortality (Anand Kumar et al., 2006). 
Conventional inflammatory biomarkers, such as CRP, do not accurately reflect the 
early phase immune cell activation (Clyne & Olshaker, 1999). Hence, novel 
biomarkers for sepsis are critically needed, with a particular reference to ones that 
would allow the early detection of these immune dysfunctions. 
Previous studies have demonstrated that Furin is upregulated upon immune cell 
activation and has a key role in regulating host defense. It is readily induced upon 
both T cell and macrophage activation in toxoplasma- and mycobacteria-infected 
animals (Ojanen et al., 2015; Oksanen et al., 2014). Further human studies have 
additionally strengthened its connection with the pathogenesis of various 
inflammatory conditions (Hipp et al., 2013; Kumar et al., 2014; Meissner et al., 2013; 
Pesu et al., 2006, Pesu et al., 2008; Shiryaev et al., 2007; Turpeinen et al., 2011). 
Because a part of Furin is secreted to the extracellular space, Furin levels can be 
reliably assessed in fluids. Here, we determined Furin plasma levels in a group of 
first-aid patients with suspected infection, using a commercial ELISA Kit (R&D 
Systems, Sigma-Aldrich). The central aim was to evaluate the biomarker potential of 
Furin plasma measurements in the early phase diagnostics and clinical decision-
making. The results of our study indicated that Furin is not suitable as an early phase 
diagnostic biomarker for suspected infection in the ER, at least when measured with 
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the aforementioned ELISA kits. Our Furin plasma measurements from first-aid 
patients with suspected infection appeared to bring no additional value in treatment 
planning or assessment of the final prognosis. Our results also indicated that Furin 
does not reflect the bacterial species, gram staining, or ultimate case fatality. 
However, we found that patients with underlying rheumatic diseases tend to have 
significantly higher Furin plasma levels when compared to healthy controls. 
Furthermore, Furin expression during infectious conditions appeared to have a 
connection with patients’ smoking habits, as nonsmokers had considerably higher 
Furin concentrations in plasma than healthy controls generally. 
Our finding concerning the elevated Furin expression in rheumatic diseases is 
consistent with previous studies because increased Furin expression and activity has 
been demonstrated in the inflamed synovial pannus in RA (Lin et al., 2012). Even 
though the fundamental role of Furin in the pathogenesis of autoimmunity is still 
unclear, Furin appears to have a key regulatory role in the maintenance of peripheral 
self-tolerance. It promotes the bioavailability of the anti-inflammatory TGF-β1 and 
regulates proper anti-inflammatory functions of CD4+ FoxP3+ Treg cells (Pesu et 
al., 2008). Interestingly, the systemic use of recombinant Furin has been shown to 
suppress inflammation and prevent joint destruction in experimental collagen-
induced arthritis in a mouse model (Lin et al., 2012). According to that, elevated 
Furin plasma levels could reflect a compensatory attempt to harness overly active 
host defense by anti-inflammatory response activation. However, because T-cell-
expressed Furin also regulates TH1/TH2-cell-type polarization by favoring a TH1-
cell-type response, further studies are clearly needed to understand the 
immunoregulatory role of Furin in plasma (Oksanen et al., 2014). 
The fact that smoking is one of the most relevant environmental risk factors for 
RA places our finding suggesting an association between high Furin expression and 
nonsmoking to an intriguing position (Klareskog et al., 2006). Because smoking is 
generally demonstrated to induce proinflammatory cytokine secretion and stimulate 
chronic inflammation, the association appears somewhat counterintuitive (Lee, 
Taneja, & Vassallo, 2012). Perhaps prolonged smoking leads to increased 
presentation of antigens in the lungs. This could cause a constant susceptibility state 
for the breakdown of immunological tolerance and lead to strong Furin expression 
during immune cell activation. Hence, Furin would not be elevated as excessively 
among nonsmokers during an acute infection. The other explanation could be that 
tobacco-related substances in plasma interfere with the Furin measurement, hence 
falsifying our data. Therefore, analyzing Furin mRNA or protein expression directly 
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in the lungs could provide more reliable data on the effect of smoking on Furin 
levels. 
To our knowledge, the usability of Furin as a diagnostic biomarker for infections 
has not been previously assessed. Because of the comprehensive and randomly 
collected study group, the presented findings are well generalized to the Finnish 
population. Although measuring Furin in plasma samples was not valuable in clinical 
decision-making in this study, we could not exclude the potential usability of Furin 
levels lower than 370 pg/ml. More sensitive measurement techniques are needed to 
evaluate the importance of lower Furin plasma levels. Altogether, the presented 
findings call for further investigations relating to the potential use of Furin plasma 
measurements as a biomarker for autoimmune diseases. 
6.2 Furin in pSS 
pSS is a systemic autoimmune disease that mainly affects the lacrimal and salivary 
glands. Dysfunctions in both humoral and T-cell-mediated immune responses cause 
excessive activation and proliferation of autoreactive immune cells, leading to 
ultimate gland destruction (Nocturne & Mariette, 2013). However, because the 
fundamental mechanisms behind pSS are still unclear, clinicians have no specific 
diagnostic methods to detect incipient pSS (Vitali, 2002). This leads to delayed, or 
even missed, diagnosis and causes significant damage and disability. Novel 
biomarkers for pSS, and for autoimmunity in general, are critically needed to avoid 
these irreversible injuries. The proprotein convertase enzyme Furin is highly 
expressed in TH1 cells and has a key regulatory role in the maintenance of peripheral 
tolerance (Pesu et al., 2008). It has previously been shown to associate with various 
diseases presenting nonresolving inflammation, such as atherosclerosis, arthritis, and 
SLE (Lin et al., 2012; Turpeinen et al., 2011; Wu et al., 2016). Consistent with earlier 
findings, our previous study considering first-aid patients with suspected infection 
(I) suggested that high Furin plasma levels are associated with diagnosed rheumatic 
diseases. These aforementioned reasons prompted us to evaluate the potential value 
of Furin measurements in the context of autoimmunity. 
In study II, we investigated Furin expression levels in pSS to assess its usability 
as a clinical biomarker is this patient group. Because our previous measurements of 
Furin plasma levels using a commercial ELISA Kit failed to detect low protein levels, 
we wanted to improve our determination methods for this study. Hence, we used 
other manufacturer’s ELISA Kit and decided to add mRNA determinations to our 
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assessments in order to get better insights into Furin expression. The transcripts of 
Furin mRNA were determined from isolated PBMCs, using the Q-RT-PCR method 
as described in Section 4. 
In study II, we demonstrated that both high Furin plasma levels and high Furin 
mRNA expressions are associated with elevated plasma levels of the 
proinflammatory cytokine IFN-γ. This type II IFN is predominantly secreted from 
T lymphocytes and has been shown to coordinate various cellular acts in host 
defense. IFN-γ, for example, mediates Th1 cell functions, activates macrophages, 
and facilitates Ig class switching (Boehm, Klamp, Groot, & Howard, 2002; Carnaud 
et al., 1999; Finkelman, Katona, Mosmann, & Coffman, 1988; Young & Hardy, 
1995). Moreover, elevated IFN-γ expression has been universally associated with the 
presence of systemic autoimmunity (Pollard et al., 2013). In pSS, more precisely, 
IFN-γ has been shown to be important in the development of glandular destruction 
(Nocturne & Mariette, 2013). Interestingly, both Furin mRNA and IFN-γ are 
expressed in TH1 cells and regulated via the same IL-12/STAT4 pathway. Hence, 
TH1 cells express these molecules simultaneously, which can partly explain this 
relationship (Pesu et al., 2006; Pollard et al., 2013). Nevertheless, in this study we 
demonstrated the association between elevated Furin and IFN-γ protein levels in PB 
for the very first time. 
In the present study, we also demonstrated that altered Furin plasma levels 
associate with clinical parameters in pSS. Patients with pSS having an increased Furin 
plasma level appeared to suffer from a considerably longer duration of the symptoms 
of dry eye. However, we also noted a nonsignificant trend in which patients with pSS 
having high Furin plasma levels seemed to possess relatively lower rates in disease 
activity indicators, such as serum β2-microglobulin levels and ESR levels, as well as 
the systemic disease activity index ESSDAI. Previous studies have been arguing for 
a crucial role for Furin in the maintenance of peripheral tolerance by dictating the 
functional maturity of TGF-β1 (Cordova et al., 2016; Pesu et al., 2008). In addition, 
Furin deletion results in impaired Th cell functions because it has been shown to 
associate with the development of less protective FoxP3+ Treg cells and oversensitive 
effector T cells with reduced susceptibility for suppressive signals of wild-type Treg 
cells (Pesu et al., 2008). 
Because elevated Furin plasma levels were nonsignificantly associated with a 
trend toward milder clinical findings, our results could argue for a potential 
symptom-reducing function of Furin in pSS. As previously mentioned, similar results 
have been reported in studies investigating systemic Furin in patients with RA, where 
it was shown to reverse the TH1/TH2 balance in inflamed joints and lead to a greater 
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proportion of Treg cells in the spleen (Lin et al., 2012). The fact that active Furin has 
been shown to prevent the production of proinflammatory cytokines in 
macrophages (Cordova et al., 2016) additionally supports its protective role in 
nonresolving inflammation. However, the fundamental nature of Furin in regulating 
the immune system appears to be multifaceted. Although an important anti-
inflammatory role of Furin seems evident, it also performs an important 
proinflammatory function, as it promotes various proinflammatory cytokines 
including BAFF (Turpeinen et al., 2011). Further studies of FUR gene expression 
showed no connections with demographic, clinical, or immunological features of 
study patients, indicating that the assessment of Furin mRNA from isolated PBMCs 
is not useful for facilitating the assessment of disease activity or severity in this 
patient group. 
To our knowledge, this is the first study assessing general protein levels of Furin 
in plasma and expression of the FUR gene in PBMCs in a study population of both 
patients with pSS and healthy controls. Therefore, relatively little is currently known 
about the Furin levels in pSS. T-cell-expressed Furin could act as a compensatory 
mechanism to prevent autoimmune responses and an overly activated immune 
system orchestrated by IFN-γ. In parallel, an exogenous Furin has been successfully 
used to harness autoimmunity in experimental animal models (Lin et al., 2012). 
However, further studies are needed to refine the knowledge of the potential clinical 
usability of Furin in pSS. 
6.3 Furin in RA 
The prevalence of chronic inflammatory diseases is rising rapidly, and RA alone is 
estimated to affect around 1% of all adults (Silman & Pearson, 2002). Because our 
understanding of the pathological mechanisms that lead to organ damage is still 
incomplete, currently used diagnostic methods and antirheumatic therapy lack 
efficacy and specificity. Hence, RA attributes a significant economic burden on our 
society. There is an increasing need for specific biomarkers for rheumatic diseases, 
with a particular reference to ones that would allow early detection and identification 
of patients who benefit from anticytokine treatment. Further, conventional 
inflammatory markers, such as CRP, do not accurately reflect the disease activity, 
which complicates the evaluation of the efficacy of a given therapeutic strategy (Orr 
et al., 2018). As discussed earlier, Furin is an important regulatory factor in both 
cellular homeostasis and pathogenesis of various diseases. It is shown to regulate the 
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bioavailability of anti-inflammatory TGF-β1 and appears to have a key role in 
restraining autoimmune responses and maintaining general immune tolerance 
(Oksanen et al., 2014; Pesu et al., 2006, Pesu et al., 2008). Previous studies have 
reported elevated Furin levels in the synovial pannus in RA and salivary gland 
biopsies in pSS (Lin et al., 2012). In addition, Furin has been found to be upregulated 
in patients with SLE (Wu et al., 2016). Consistently, our studies of Furin plasma 
levels and isolated PBMCs indicate that it might have a role in the pathogenesis of 
autoimmune diseases (I and II). In more detail, upregulated Furin was reported in 
plasma in patients with suspected infection or underlying rheumatic disease (I) and 
in isolated PBMCs in pSS (II). 
In study III, we investigated Furin levels in patients with active RA and healthy 
controls to evaluate the potential value of Furin as a biomarker for RA and 
autoimmunity in general. Because our previous determinations of Furin mRNA 
from isolated PBMCs failed to present a significant value for clinical use in pSS (II), 
we wanted to broaden our methods for Furin mRNA determinations in order to 
achieve a better understanding of their usability in clinical practice. Consequently, 
here, we isolated mononuclear cells additionally from the synovial fluid samples of 
patients with active RA to determine local Furin mRNA expression in inflamed 
joints. To our knowledge, this was the first study to evaluate Furin expression in 
tissue-infiltrating leukocytes in RA. Our analyses showed that Furin mRNA 
expression was significantly elevated in active RA, suggesting that Furin is 
upregulated in two different rheumatic disease types. However, further research is 
required to evaluate if Furin is upregulated in rheumatic diseases generally. 
In the next section of study III, we assessed how Furin levels correlate with the 
demographic and clinical parameters in RA to evaluate its potential role in diagnosis 
and treatment planning. Our findings showed that elevated Furin mRNA expression 
is associated with high-dose prednisolone treatment, increased levels of conventional 
inflammation markers CRP and ESR, and a greater HAQ disability index. These 
findings suggest that, contradictory to pSS, a high Furin level is associated with more 
active and severe RA. This is somewhat surprising, as Furin is known to generally 
promote peripheral tolerance and restrain proinflammatory cytokine secretion 
(Cordova et al., 2016; Pesu et al., 2008). Further, previous studies have argued for a 
protective role of Furin in arthritis (Lin et al., 2012). Consistently, Furin inhibition 
has been demonstrated to promote an invasive phenotype of synoviocytes in patients 
with RA Our present observation of increased Furin levels in severe RA may be 
explained as a compensatory attempt to suppress excessive inflammation. 
Analogously, previous studies have reported increased levels of other anti-
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inflammatory agents as well, including IL-10 and TGF-β, in active RA (McInnes, 
Buckley, & Isaacs, 2016). However, abundant presence of pro-inflammatory 
mediators leads to persisting inflammation despite these enforced suppressive 
functions. Hence, the Furin expression could be high simply because it rises in the 
immune activation in general. 
Finally, we investigated how Furin levels associate with universally expressed 
plasma cytokines. The analysis showed that patients with elevated Furin levels also 
tend to have elevated plasma levels of other global cytokines, most significantly 
proinflammatory IL-2. Because elevated IL-2 levels are a previously reported sign of 
T cell activation, this finding is consistent with previous studies reporting that Furin 
is enhanced upon macrophage and T cell activation (Pesu et al., 2008; Turpeinen et 
al., 2011).  
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7 CONCLUSIONS AND FUTURE PERSPECTIVES 
In the present study, the expression levels of a PCSK enzyme Furin were investigated 
in different IMDs, using ELISA and Q-RT-PCR methods. In addition, Furin levels 
were associated with clinical and demographic parameters to assess the potential 
value of Furin measurements as a biomarker in clinical practice. For the first time, 
we demonstrated that Furin plasma levels, at least when determined by particular 
commercial ELISA kits, cannot be used as a diagnostic or prognostic biomarker for 
first-aid patients with suspected infection in the ER. Moreover, it brings no value for 
decision-making in treatment planning. 
However, analyses from all three presented studies suggest that Furin expression 
is elevated in autoimmune diseases. We also showed that Furin is upregulated in 
different rheumatic disease types, more specifically in pSS and RA. Interestingly, our 
results show contradictory suggestions of the association between Furin and the 
pathogenesis of these diseases. Investigations of Furin expression in patients with 
pSS indicated a protective role of Furin in the pathogenesis of pSS, as Furin 
upregulation was related to signs of somewhat lower disease activity. In contrast, an 
elevated Furin expression was associated with more severe and treatment-resistant 
RA. One possible explanation for these rather contradictory results could be that 
Furin has a disease-specific function. In other words, because Furin cleaves both 
anti-inflammatory (e.g., TGF-β1) and proinflammatory (e.g., TNF family cytokines 
and tumor necrosis factor-alpha converting enzymes) factors, its final effects on the 
immune system can differ greatly on the basis of pathological mechanisms of the 
diseases (Thomas, 2002). However, further studies and more sensitive Furin 
measurements with larger study groups are needed to investigate the clinical 
relevance of presented findings and to refine the potential value of Furin as a 
biomarker for autoimmune diseases.  
Here, we have shown that the used commercial ELISA kits clearly lack sufficient 
sensitivity and fail to detect low Furin levels in human plasma samples. However, 
alternative Furin measurement technologies, such as determining Furin activity in 
fluidic samples using fluorogenic substrates, could yield different results. 
Importantly, PCSK activity measurements should be optimized to serum or plasma 
and it is not specific for Furin. In addition, other plasma proteins may interfere with 
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activity measurements because the current functionality is only based on in vitro 
experiments (Cork et al., 2012).  We have also shown that the use of the Q-RT-PCR 
method can generate additional information on Furin levels independently of ELISA 
measurements. We did not face any problems in determining Furin mRNA levels 
from isolated mononuclear cells, but because of the small sample size, the 
fundamental functionality should be further tested on a larger patient group. 
A greater focus on investigating new methods for measuring Furin expression 
could reveal new aspects for the clinical usability of Furin. One of the newest 
detection methods is the proximity extension assay technique with the O-LINK 
reagent kit, consisting of two highly specific oligonucleotide-labelled antibodies. 
They form ligations with their target proteins in plasma and can be further quantified 
using the Q-RT-PCR method (Assarsson et al., 2014). The O-LINK method has 
recently been reported to be successful in detecting Furin levels in patients with 
diabetes mellitus, and postural orthostatic tachycardia syndrome (Fernandez et al., 
2018; Spahic et al., 2019). Altogether, novel methods for the detection of Furin can 
provide better ways to understand the fundamental nature of this ubiquitous 
endoprotease and its value as a biomarker for distinct IMDs. 
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Abstract
There is an increasing need for novel biomarkers that enable better diagnostic
and prognostic stratiﬁcation of patients with suspected infection. A proprotein
convertase enzyme FURIN is upregulated upon immune cell activation, and it
promotes infectivity by cleaving and activating pathogens. In this study, we
determined FURIN levels in plasma using ELISA from 537 patients that were
admitted to emergency room with suspected infection. Patients were sorted to
high- and low-level FURIN groups with a cut-off level of 370 pg/ml. The study
cohort included ﬁve diagnostic groups: Group 1, no systemic inﬂammatory
response syndrome (SIRS, n = 59 patients); Group 2, bacterial infection without
SIRS (n = 67); Group 3, SIRS, but no bacterial infection (n = 308); Group 4,
sepsis without organ failure (n = 308); and Group 5, severe sepsis (n = 49).
Statistically signiﬁcant associations were not found between the plasma level of
FURIN and the prevalence of sepsis (P = 0.957), diagnostic group of a patient
(P = 0.737) or the bacteria in blood culture (P = 0.499). Additionally, the
concentration of FURIN did not predict the severity or case fatality of the
infectious disease. However, statistically signiﬁcant associations were found
between high plasma level of FURIN and diagnosed rheumatic disease
(P < 0.001) as well as with the prevalence of non-smokers (P = 0.034). Thus,
albeit the plasma level of FURIN does not predict the severity of infectious
disease, it may be of use in the diagnostics of autoimmune diseases.
Introduction
Sepsis is a major cause of mortality. In severe sepsis,
mortality rises up to 60–70% [1, 2]. Potentially fast disease
progression is the main reason why early diagnosis and quick
adequate treatment are extremely important in this condi-
tion. Even an hour-long delay in adequate antimicrobial
treatment may have an adverse impact on prognosis [3, 4].
Currently used biomarkers for the diagnosis of sepsis are
C-reactive protein (CRP), blood leucocytes and procalci-
tonin (PCT) [5, 6]. None of these biomarkers are suitable
for the early stages of sepsis; they can be used for
conﬁrmation, but not for exclusion of the diagnosis. For
example, CRP levels begin to rise only after 12 h of the
early signs of sepsis and it is not a speciﬁc marker of
bacterial infection [7, 8].
The proprotein convertase subtilisin/kexin (PCSK)
enzymes belong to the subtilisin superfamily of serine
endoproteases, which convert immature precursor proteins
into the biologically functional units by catalysing post-
translational site-speciﬁc hydrolytic cleavage [9, 10].
FURIN is the ﬁrst found and therefore the most studied
mammalian proprotein convertase. This ubiquitously
expressed enzyme is located mainly in the trans-Golgi
network (TGN) of the secretory pathway. In addition,
FURIN cycles between TGN and the cell surface via the
endosomal system, and a proportion of it is secreted to the
extracellular space [11, 12]. Because FURIN is widely
expressed, its activity regulates the maturation of numer-
ous precursor proteins. Its substrates include various
growth factors and their receptors, enzymes, hormones,
cytokines, serum proteins, as well as extracellular matrix
proteins [10, 11]. In addition to FURIN’s crucial function
in the maintenance of cellular homoeostasis, it is also
involved in the pathogenesis of several diseases. For
example, increased FURIN levels are associated with
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aggressive cancers and metastatic activity [11], and it is
highly expressed in chronically inﬂamed tissues in rheuma-
toid arthritis (RA) and atherosclerosis [13, 14]. FURIN has
also a signiﬁcant role in the activation of viruses and
bacterial pro-toxins. These pathogens include bird ﬂu
(AH5N1), HIV and Ebola viruses as well as the toxins of
Bacillus anthracis and Clostridium botulinum [12].
Because FURIN is essential for the embryogenesis, our
understanding on its cell-type-speciﬁc in vivo function is
incomplete [13]. However, we have previously shown that
FURIN is profoundly upregulated in T helper type 1 (Th1)
cells via the IL-12/Stat4 pathway and by T cell receptor-
mediated signalling [15]. T cell-expressed FURIN regu-
lates the Th cell polarization and the peripheral immune
tolerance primarily by controlling the functional matura-
tion of anti-inﬂammatory cytokine transforming growth
factor-beta (TGF-b1) [15–17]. In macrophages, the expres-
sion and secretion of FURIN is induced by lipopolysac-
charide (LPS) [18, 19], and a FURIN-like enzyme controls
the quantity and activation of the human Toll-like receptor
7 (TLR7) [20]. In contrast, relatively little is known about
the FURIN levels in human infections, but an elevated
serum concentration has been reported in chronically
Salmonella typhi-infected patients [18].
The fact that FURIN is upregulated upon immune cell
activation and its key regulatory role in host defence
prompted us to evaluate the usability of plasma FURIN as
an early stage infection biomarker. Speciﬁcally, we analysed
whether the proprotein convertase FURIN levels in plasma
could be useful in predicting the severity and case fatality
of infection in a large, randomly selected cohort of patients
that were admitted the emergency room with suspected
infection.
Methods
Study population. The study population was recruited in the
Satakunta Central Hospital, Finland within a 14-month
study period in 2004 to 2005 [6, 21–23]. Satakunta
Central Hospital is a secondary care hospital with 350-beds
serving a population of 240 000 inhabitants. There are no
other hospitals with an emergency room and an intensive
care unit (ICU) in the Satakunta area. All of the involved
patients were adults, who had been admitted to the
emergency room with a suspected infection status and been
drawn a blood culture sample. The study was approved by
the Ethical Review Board of the Satakunta Hospital
District. Written informed consent was obtained from
patients or close relatives. To ensure written informed
consent and interview within 24–48 h, only patients
admitted between Sunday 7 a.m. and Wednesday 3 p.m.
were enrolled [23].
The plasma samples were taken simultaneously with the
blood culture samples and collected in two 10-ml EDTA
tubes. The EDTA tubes were kept on ice before the
centrifugation in 2500 G-force for 10–15 min. The
samples were then transported in 1 to 2 ml aliquots to
CryoPure (Sarstedt, Germany) tubes and further stored at
70 °C [23].
The information for the statistical analysis was obtained
from an interview held by a researcher or a research nurse
within 24–48 h after the admission. Highest body tem-
perature, lowest blood pressure, highest pulse and the
respiratory rate were measured daily during the ﬁrst week
of hospitalization. In addition, symptoms and clinical
signs, Glasgow coma scale, risk factors for sepsis, under-
lying disease, diagnosis at admission, prospective organ
failure (cardiovascular, haematological, hepatic, renal,
respiratory or central nervous system), universal case
fatality and the case fatality caused by sepsis were
documented in ICU and in the ward. Other information
such as the potential reason and the cause of the infection
and trauma together with the ﬁnal diagnose was checked
from patient’s medical records. Follow-up surveys were
conducted by phone 3 months and one year after patient’s
admission. Before initiating the study, a pre-evaluation of
the target population was conducted to ensure the
representativeness of the cohort. This assessment covered
1551 consecutive patients from whom blood had been
collected in the emergency department for blood culture.
The rate of positive blood culture in the pre-evaluation was
8.3%, and case fatality by day 28 after admission was
6.7%. No signiﬁcant differences in age, gender, rate of
positive blood culture or mortality were noted between
patients admitted on study days and those admitted on
other days, or between the study and the pre-evaluation
populations. [23]
In total, blood samples were taken from 609 patients.
Fifty-ﬁve samples were removed because of the patient’s
reluctance to participate in the research, and 17 samples
were left out from other reasons: 1 missing, 11 unclear
results, 3 with SIRS and multi-organ failure but no
bacterial infection and two samples ran out. As a result, the
ﬁnal cohort comprised of 537 patients [23].
Measurement of plasma FURIN levels. The concentration
of proprotein convertase FURIN was determined from
EDTA plasma samples using a commercial Human FURIN
enzyme-linked immunosorbent assay (ELISA) kit (Sigma-
Aldrich, USA) according to manufacturer’s instructions.
The reliable detection limit of the assay was determined to
be 370 pg/ml, and the concentrations below that were
considered as low/absent. In general, all samples were
analysed once, but analysis was replicated with a higher
dilution for the samples showing exceptionally high
FURIN levels. The patients were stratiﬁed into low and
high plasma FURIN groups with a cut-off at 370 pg/ml.
Statistical analysis. The detected FURIN concentrations
were transferred to the SPSS Statistics for Windows
software (IBM, version 22) for statistical analyses. The
study population was divided into ﬁve diagnosis groups
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based on the American Collage of Chest Physicians/Society
of Critical Care Medicine Consensus Conference deﬁnitions
of the severity of the infection stage [24].
Nonparametric independent-samples t-test for indepen-
dent samples or analysis of variance was used with normally
distributed variables, and Mann–Whitney U-test or
Kruskal–Wallis test for the rest. Two binomial variables
were analysed with chi-square or Fisher’s exact test. Linear
regression and logistic regression were used to examine the
effect of potential confounders. The Kaplan–Meier and the
log-rank test were used to investigate the connection
between the FURIN levels and the case fatality.
The common signiﬁcance levels were used to determine
the importance of the outcomes: P < 0.05 illustrated a
statistically signiﬁcant result, and P < 0.001 was consid-
ered as a statistically highly signiﬁcant discovery.
Results
The demographic data of the study population (n = 537),
underlying diseases as well as the infection-associated
clinical parameters during the ﬁrst 28 days, are presented
in Table 1. The plasma FURIN levels were measured from
all samples as described in methods. The assay standard
curve was prepared using serial dilutions of recombinant
FURIN protein, and a reliable linearity was detected only
with FURIN levels above 370 pg/ml, which was thus
determined as cut-off for high FURIN levels in plasma.
The cohort was stratiﬁed into ﬁve study groups on the basis
of ACCP/SCCM Consensus Conference deﬁnitions
(Table 2) [24] and further divided into low and high
FURIN samples. In the ﬁve different groups, high FURIN
levels were detected in 14.9% - 22.0% of samples, with
lowest percentage of high FURIN samples in bacterial
infection, no SIRS group (Group 2) and highest in no SIRS,
no bacterial infection group (Group 1). However, differ-
ences in the prevalence of high FURIN levels between
different groups were not signiﬁcant (P = 0.737).
We next assessed whether high FURIN level in plasma
is associated with patients’ demographic characteristics
or infection-associated clinical parameters (Table 3).
Although elevated FURIN levels have been found in
malignancies and atherosclerosis [11, 13, 25], there were
no statistically signiﬁcant associations with high
FURIN plasma levels and the prevalence of solid cancer
(P = 0.606) or cardiovascular diseases (P = 0.204). How-
ever, in keeping with the elevated FURIN expression in
inﬂamed tissues in RA [14], FURIN plasma concentrations
over 370 pg/ml were associated highly signiﬁcantly with a
diagnosed rheumatic disease. Speciﬁcally, only 7.0% of the
patients in the group with lower levels of FURIN were
suffering from rheumatic diseases in contrast to 18.5% in
the high FURIN level group (P < 0.001). The plasma
level of FURIN was over 370 pg/ml in 40% of arthritis
patients compared to only 18% in the cohort without
rheumatic disease (data not shown). Interestingly, albeit
tobacco smoking places a burden on the immune system,
and could thus be envisioned to increase FURIN expression
through the immune cell activation, we also found a
signiﬁcant association between current smokers and low
FURIN plasma levels (P = 0.034).
In contrast, during the ﬁrst 28 days, FURIN plasma
levels did not signiﬁcantly associate with any of the
investigated clinical parameters including multi-organ
failure (P = 0.421) or the occurrence of sepsis
(P = 0.957); also there was no statistically signiﬁcant
Table 1 Demographic and clinical characteristics of the study population
(N = 537).
N Percentage
Characteristic
Age, median (range) 64.2 (18–100)
Gender (male) 310 57.7
Obesity (BMIa ≥30 kg/m2),
median (range)
27.0 (14.7–67.6)
Alcohol abuseb 25 4.7
Smoking (current smoker) 126 23.5
Diabetes (types 1 and 2) 81 15.1
Solid cancer 78 14.5
Malignancy (solid or
haematological)
95 17.7
Rheumatic disease 50 9.3
Chronic renal insufﬁciencyc 18 3.4
Cardiovascular diseased 289 53.8
Continuous cortisone treatmente 59 11.0
Clinical parameters (day 0–28)
Case fatality (d 28) 33 6.1
Case fatality (d 90) 58 10.8
Case fatality (1 year) 112 20.9
ICUf stay needed 42 7.8
Hypotensiong 28 5.2
DICh 8 1.5
Decreased GCSi 60 11.2
Mechanical ventilation 14 2.6
C-PAP/bi-PAPj 22 4.1
Sepsis + organ dysfunction 49 9.1
MOFk 10 1.9
Demographics are reported as a number and percentage except age and
obesity which are reported as median and range.
aBody mass index, data available on 390 patients.
bAlcoholism was diagnosed or patient had previously been treated for
alcohol-induced disease.
cPlasma creatinine concentration continually more than 170 lmol l1
(ﬁve patients underwent chronic dialysis treatment).
dContinuous medication for cardiovascular disease (including hypertension
and arteriosclerosis).
eContinuous systemic cortisone treatment (daily dose >10 mg oral
prednisolone).
fIntensive care unit.
gSystolic blood pressure < 90 mmHg or a reduction of 40 mmHg from
baseline. No response to 500 ml intravenous ﬂuid replacement.
hDisseminated intravascular coagulation.
iGlasgow coma scale <15.
jContinuous positive airway pressure/bilevel positive airway pressure.
kMulti-organ failure.
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connection to a 28-day case fatality when examining
patients with sepsis as a direct cause of dead or a
contributing factor on patient’s decease (P = 0.463). In
conclusion, the current data imply that assessing FURIN
plasma levels does not have value as a diagnostic marker for
patients with a suspected infection.
To investigate whether FURIN plasma levels could
associate with the Gram staining results of the blood
culture samples, we divided the study population into four
groups with the alternatives of no growth, Gram-positive,
Gram-negative and mixed infection (Table 4); no signif-
icant differences in FURIN levels were observed
(P = 0.351). To explore the more accurate distribution of
various bacterial species into the two FURIN plasma levels,
the blood culture results were further divided into the
Gram-positive and Gram-negative bacterial species
(Table 5). Gram-negative Escherichia coli (n = 11) and
Gram-positive Streptococcus pneumoniae (n = 10) were notice-
ably the most common causes of a systemic bacterial
infection among our study cohort. However, the ﬁndings
again indicated that FURIN plasma levels measured
simultaneously with the blood culture sampling are not
informative considering the bacterial strain causing the
infection.
To estimate the potential use of FURIN as a marker for
a patient’s prognosis in predicting the severity and the case
fatality, we constructed two survival curves. First, we
examined the overall case fatality during the 1-year study
period (Fig. 1). The plasma level of FURIN failed to
prognosticate the case fatality of an infection in a 1-year
lasting follow-up period (P = 0.742). Finally, we wanted
to clarify the possible prognostic value of FURIN concen-
trations especially among the patients who had been
diagnosed with sepsis at the emergency room. According to
the fact that basically all of the sepsis-related deaths occur
in the ﬁrst four weeks since the symptoms had started, we
limited the follow-up time into 28 days. The cases where
sepsis was not a direct cause of dead or did not contribute
to patient’s decease were censored (n = 13) from the
analysis (Fig. 2). The statistical signiﬁcance was not found
between the survival probability of septic patients and
FURIN concentration level (P = 0.898).
Discussion
We examined the usability of the ubiquitously expressed
proprotein convertase FURIN as an infection biomarker by
determining its plasma concentrations in the study cohort
of 537 patients admitted to the emergency room with a
suspected infection. The present results revealed that
FURIN cannot be used as a diagnostic biomarker at the
emergency room in the early phase of an infection, even
though it has earlier been associated with various inﬂam-
matory conditions [12, 13, 15, 17–20]. There were also no
statistically signiﬁcant associations between the FURIN
plasma levels and the Gram staining or the bacterial species
of the blood cultures. The concentration of FURIN neither
associated with the case fatality or the severity of the
infection in our study cohort. In contrast, we found that
patients with a rheumatic disease and patients that were
not currently smokers had signiﬁcantly more frequently
high plasma concentrations of FURIN.
Table 2 The distribution of emergency room patients stratiﬁed by diagnosis group into low or high FURIN levels.
Diagnosis group Criteria
FURIN < 370 pg/ml
(N = 429)
FURIN ≥ 370 pg/ml
(N = 108)
n Percentage n Percentage
1. No SIRS, no bacterial
infection (N = 59)
Patients with no SIRSa (less than two SIRS criteria 24 h)
or documentedb or probablec bacterial infection
46 78.0 13 22.0
2. Bacterial infection,
no SIRS (N = 67)
Patients with documental or probable bacterial infection,
but no SIRS (less than two SIRS criteria 24 h)
57 85.1 10 14.9
3. SIRS, no bacterial
infection (N = 54)
Patients with SIRS (at least two SIRS criteria 24 h), but
no documental or probable bacterial infection
45 83.3 9 16.7
4. Sepsis (N = 308) Patients with sepsis (SIRS and documented or probable
bacterial infection but no dysfunction due to sepsis)
242 78.6 66 21.4
5. Severe sepsis (N = 49) Patients with severe sepsis (sepsis with signs of organ
failure, that is distributed perfusion, metabolic acidosis,
oliguria or neurological disorders)
39 79.6 10 20.4
Differences between ﬁve groups were studied using the chi-square test (P = 0.737).
aSystemic inﬂammatory response syndrome (SIRS): at least two of the following conditions. 1. Temperature >38 °C or <36 °C; 2. Heart rate >90 beats per
min; 3. Respiratory rate >20 breaths per min or partial pressure of carbon dioxide in arterial blood [PaCO2] <32 mmHg (4.3 kPA). 4. White blood cell
count >12 9 109 l1 or >10% immature (band) forms.
bDocumented bacterial infection: microbiologically conﬁrmed bacterial infection (either pathogenic bacterial growth in blood culture or in normally sterile
tissue or the same usually less pathogenic bacterium, for example Staphylococcus epidermidis, in two different samples).
cProbable bacterial infection: a clinician suspected bacterial infection and either infection focus was conﬁrmed or antimicrobial treatment was started and
the response to treatment supported bacterial infection.
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The strong association of the elevated plasma FURIN in
patients with a rheumatic disease is consistent with the
earlier ﬁndings showing upregulated FURIN in the
inﬂamed joints of patients with RA [14]. The role of
FURIN in autoimmune diseases is not fully understood,
but its expression in T cells is critical for the functional
maturation of pro-TGF-b1 and adequate function of CD4+
Foxp3+ T regulatory cell-dependent immune tolerance
[17]. Moreover, administration of the recombinant FURIN
alleviates the inﬂammation in an experimental collagen-
induced arthritis (CIA) mouse model [14]. Theoretically,
elevated FURIN levels in plasma could thus reﬂect an
attempt to harness overly active host defence by the
activation of anti-inﬂammatory responses. However, as T
cell-expressed FURIN also inhibits Th2 responses and
Table 4 The distribution of the Gram staining of bacteria in blood
culture ﬁndings into the FURIN levels.
Blood culture ﬁnding
FURIN <
370 pg/ml
(N = 429)
FURIN ≥
370 pg/ml
(N = 108)
N Percentage N Percentage
No growth (N = 485) 389 80.2 96 19.8
Gram-positive (N = 28) 20 71.4 8 28.6
Gram-negative (N = 16) 12 75.0 4 25.0
Mixed (N = 7) 7 100.0 0 0.0
Differences between ﬁve groups were studied using the chi-square test
(P = 0.351).
Table 3 The distribution of patients’ demographic characteristics and
clinical parameters into the two FURIN levels (N = 537).
FURIN <
370 pg/ml
(N = 429)
FURIN ≥
370 pg/ml
(N = 108)
P-valueN Percentage N Percentage
Characteristic
Age, median (range) 63.82 (18–100) 66.38 (20–94) 0.618
Gender (male) 246 57.35 64 59.3 0.719
Obesity (BMIa ≥
30 kg/m2),
median (range)
27.20 (14.7–62.5) 26.67 (15.1–67.6) 0.320
Alcohol abuseb 22 5.1 3 2.8 0.300
Smoking
(current smoker)
109 25.4 17 15.7 0.034
Diabetes
(types 1 and 2)
68 15.9 13 12.0 0.322
Solid cancer 64 14.9 14 13.0 0.606
Malignancy (solid or
haematological)
79 18.4 16 14.8 0.381
Rheumatic disease 30 7.0 20 18.5 <0.001
Chronic renal
insufﬁciencyc
16 3.7 2 1.9 0.333
Cardiovascular
diseased
225 52.4 64 59.3 0.204
Continuous cortisone
treatmente
42 9.8 17 15.7 0.077
Clinical parameters (day 0–28)
Case fatality (day 28) 28 6.5 5 4.6 0.463
Case fatality (day 90) 49 11.4 9 8.3 0.355
Case fatality (1 year) 90 21.0 22 20.4 0.889
ICUf stay needed 30 7.0 12 11.1 0.154
Hypotensiong 23 5.4 5 4.6 0.760
DICh 7 1.6 1 0.9 0.588
Decreased GCSi 50 12.2 10 9.6 0.460
Mechanical
ventilation
11 2.6 3 2.8 0.901
C-PAP/bi-PAPj 16 3.7 6 5.6 0.392
Sepsis + organ
dysfunction
39 9.1 10 9.3 0.957
MOFk 9 2.1 1 0.9 0.421
Demographics are reported as a number and percentage in the particular
concentration of FURIN
Except age and obesity which are reported as median and range.
Statistically signiﬁcant p values are bolded.
aBody mass index, data available on 390 patients.
bAlcoholism was diagnosed or patient had previously been treated for
alcohol-induced disease.
cPlasma creatinine concentration continually more than 170 lmol l1
(ﬁve patients underwent chronic dialysis treatment).
dContinuous medication for cardiovascular disease (including hypertension
and arteriosclerosis).
eContinuous systemic cortisone treatment (daily dose > 10 mg oral
prednisolone).
fIntensive care unit.
gSystolic blood pressure < 90 mmHg or a reduction of 40 mmHg from
baseline. No response to 500 ml intravenous ﬂuid replacement.
hDisseminated intravascular coagulation.
iGlasgow coma scale < 15.
jContinuous positive airway pressure/bilevel positive airway pressure.
kMulti-organ failure.
Table 5 The distribution of different bacterial species measured from
blood cultures into two FURIN levels.
FURIN
< 370 pg/ml
FURIN ≥
370 pg/ml
TotalN N
Gram-positive bacteria
Stafylococcus aureus 3 1 4
Other Stafylococcus 2 2 4
Streptococcus pneumoniae 8 2 10
Other Streptococcus 4 1 5
Listeria monocytogenes 0 1 1
Anaerobic Gram-positive
bacteria/bacillus
2 1 3
Gram-negative bacteria
Escherichia coli 9 2 11
Pseudomonas 1 0 1
Other Enterobacteriuma 3 0 3
Neisseria meningitidis 0 1 1
Klebsiella 4 1 5
Anaerobic Gram-negative
bacteria/bacillus
1 0 1
Differences between values in the table were studied using the chi-square
test (P = 0.499).
aSalmonella, Morganella, Proteus, Pantotea.
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promotes Th1-type inﬂammation, further studies are
clearly required to fully understand the immunoregulatory
role of FURIN in plasma [16]. In any case, our current
ﬁnding calls for a further assessment of the value of plasma
FURIN levels as a biomarker in autoimmune diseases.
A statistically signiﬁcant association was also found
between the FURIN concentrations below 370 pg/ml and
the habit of smoking. This is somewhat counterintuitive
as smoking is generally regarded to evoke a chronic
inﬂammatory state in the body involving the expansion in
the quantity of proinﬂammatory cytokines [26]. One
possible explanation could be that tobacco-related sub-
stances in plasma interfere with the FURIN measurement
and thus falsify the data. Therefore, analysing FURIN
mRNA or protein expression directly in the lungs could
give more reliable data on the effect of smoking on
FURIN levels.
To our knowledge, this was the ﬁrst study assessing the
usefulness of proprotein convertase FURIN as a diagnostic
biomarker for the infections. The strengths of our study
were a randomly selected and comprehensive study cohort,
a high quality of information collection and the follow-up
together with the broad data on patients’ demographic and
clinical characteristics. The wide data including the
information starting from the underlying diseases and
medications as well as received treatment during the
hospital stay and rehabilitation occurred within 1-year
study time, allowed us to undergo multifarious statistical
Figure 1 The survival curve measuring the
correlation between low (N = 429) and high
(N = 108) FURIN levels and the case fatality
among the entire study population explored
during the 1-year follow-up (P = 0.742).
Figure 2 The survival curve measuring
correlation between low (N = 429) and high
(N = 108) FURIN levels and the case fatality
among the patients with the septic infection
explored during the 28-day follow-up
(P = 0.898). Deaths for which the sepsis
found in the emergency room did not
inﬂuence or was not the direct cause of the
expiration are censored from the curve
(N = 13).
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analysis. The information bias and random error were
minimized by taking the plasma samples for the study
simultaneously with the samples taken for the diagnostic
tests and deﬁning the exact timing for the interviews. This
reduced the potential occurrence of both the selection and
the information bias making the presented results largely
generalizable to the infectious patients in the Finnish
population.
The sensitivity of the FURIN ELISA kit did not
allow measurement of low FURIN concentrations, but
forced us to stratify the samples into low and high
FURIN groups. The transformation of the variable from
scale to ordinal caused a loss of information and
moreover led to the reduction of a statistical power of
our data. In addition to us, also other research teams
have reported the sensitivity of FURIN antibody assays
as problematic [27]. A more sensitive method for the
determination of proprotein convertases in plasma could
be a direct measurement of the FURIN’s activity using a
ﬂuorogenic substrate [28]. The downside is that the
concerned technique does not distinguish PCSK enzymes
from each other.
To determine the FURIN plasma levels in a healthy
population, we performed a small-scale pilot study with
six healthy volunteers (data not shown). All these samples
showed FURIN levels below the cut-off used in this
study, but a larger cohort and a more sensitive measure-
ment technique are clearly needed to obtain reliable
information on the range of normal plasma FURIN. This
may also result in reinterpretation of the current data; if
the starting levels of FURIN in healthy individuals are
highly variable, the potential rise during the infection
would have remained unnoticed even if it occurred
consistently with every patient. Also, due to lack of
sensitivity of the used ELISA kit, it cannot be excluded
that infection-associated changes below 370 pg/ml may
have a diagnostic value.
In conclusion, we have shown that plasma FURIN levels
assessed with the current method cannot be used as a
diagnostic biomarker in patients with suspected infection
and fail to predict case fatality or severity. However, even a
low sensitivity ELISA measurement implies that plasma
FURIN levels may associate with autoimmunity.
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ABSTRACT
Objective. The proprotein convertase 
enzyme FURIN is a critical regulator of 
WKHDQWLLQÁDPPDWRU\7*)ơF\WRNLQH
and peripheral immune tolerance. In 
T cells, FURIN is co-regulated with 
,)1Ƣ DQG WKXV KLJKO\ H[SUHVVHG LQ 7
helper 1 type cells. Previous studies 
have demonstrated that FURIN is up-
UHJXODWHG LQ LQÁDPPDWRU\ FRQGLWLRQV
including atherosclerosis, rheumatoid 
arthritis and systemic lupus erythema-
tosus. Here, we evaluated the levels of 
FURIN in the plasma and peripheral 
blood mononuclear cells (PBMCs) of 
patients with primary Sjögren’s syn-
drome (pSS) and in healthy controls. 
Methods. FURIN plasma levels were 
determined by ELISA, and the mRNA 
expression in PBMCs was quantitated 
using qPCR. FURIN levels in the plas-
ma were correlated with the clinical 
and demographic characteristics of the 
patients.
Results. FURIN was found to be sig-
QLÀFDQWO\XSUHJXODWHGDWERWKWKHSUR-
tein and mRNA level in pSS patients 
compared to healthy controls. In pSS 
patients, high FURIN protein levels 
ZHUH VLJQLÀFDQWO\ DVVRFLDWHG ZLWK HO-
HYDWHG ,)1Ƣ OHYHOV LQ WKH SODVPD
as well as a longer duration of sicca 
symptoms in the eyes. pSS patients 
with high FURIN levels in their plasma 
showed a trend towards lower levels of 
serum beta-2 microglobulin, ESR and 
a lower systemic disease activity index 
ESSDAI.
Conclusion. The proprotein con-
YHUWDVH)85,1LVVLJQLÀFDQWO\XSUHJX-
lated in pSS. Elevated FURIN levels 
associate with high levels of the Th1 
W\SH F\WRNLQH ,)1Ƣ DQG ORQJ GXUD-
tion of dry eye symptoms. Patients with 
high FURIN levels show signs of lower 
disease activity suggesting that FURIN 
might have a protective role in pSS.
Introduction
Primary Sjögren’s syndrome (pSS) is a 
chronic systemic autoimmune disease 
FKDUDFWHULVHG E\ O\PSKRF\WLF LQÀOWUD-
tion in the salivary and lacrimal glands 
and over-activation of B cells leading 
subsequently to hypergammaglobuli-
naemia and development of autoan-
tibodies (1, 2). According to current 
knowledge, the main pathophysiologi-
cal mechanisms in pSS are mediated 
through the interferon (IFN) I and IFN 
II pathways (1, 2). The type II cytokine 
,)1ƢKDVEHHQIRXQGWREHUHVSRQVLEOH
for the gland dysfunctions in Ro/SSA 
immunised mice. Vice versa, a reduc-
WLRQ LQ WKH OHYHO RI ,)1Ƣ RU ,)1Ƣ5
seems to inhibit the development of 
pSS (2).
The proprotein convertase subtilisin/
kexin enzymes (PCSKs) activate vari-
ous immature proteins by catalysing 
WKHLUSRVWWUDQVODWLRQDO VLWHVSHFLÀFK\-
drolytic cleavage (3). The ubiquitously 
expressed PCSK enzyme FURIN catal-
yses the proteolysis of a large number of 
substrates with immunoregulatory func-
tions including cytokines, integrins and 
viral envelope proteins (3-5). FURIN is 
upregulated in Th1 cells via the IL-12/
Stat4 pathway (6). The T-cell-expressed 
FURIN regulates Th cell polarisation 
and peripheral immune tolerance by 
controlling the functional maturation of 
WUDQVIRUPLQJJURZWKIDFWRUEHWD7*)ơ
1) (3, 6, 7). FURIN is also upregulated 
LQFKURQLFDXWRLPPXQHLQÁDPPDWLRQDV
is seen in patients with rheumatoid ar-
thritis (RA) (8) and systemic lupus ery-
thematous (SLE) (9).
The fact that FURIN is an important 
regulator of peripheral immune toler-
ance and highly expressed in Th1-type 
lymphocytes prompted us to determine 
the levels of the FURIN protein and 
mRNA in patients with pSS compared 
to healthy controls.
Proprotein convertase enzyme FURIN 
is upregulated in primary Sjögren’s syndrome
N. Ranta1,2, A. Valli1, A. Grönholm1,2, O. Silvennoinen1,3, 
P. Isomäki4,5, M. Pesu2,5,6, M. Pertovaara4,5
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Methods 
Study population
Peripheral blood (PB) samples were 
obtained from 16 (14 female and 2 
male) patients with pSS that were re-
cruited from the Centre for Rheumatic 
Diseases at the Tampere University 
Hospital, Finland. The inclusion crite-
ULDZHUH IXOÀOPHQW RI DW OHDVW IRXU RI
the revised American-European con-
sensus group criteria for pSS (10), to-
JHWKHUZLWKDFRQÀUPDWLRQRIDQDFWLYH
GLVHDVHYHULÀHGZLWKHLWKHUDQ(66'$,
>11 (11) or with laboratory tests: eryth-
rocyte sedimentation rate (ESR) >20 
mm/h serum immunoglobulin G (IgG) 
>15 mg/L, serum beta-2 microglobulin 
>2.2 mg/L or serum complement C4 
<0.10 mg/L. The median age of the pa-
tients was 53 years (range 32–80 years) 
and disease duration 11 years (range 
0–27 years). Three of the pSS patients 
used medication during sampling: one 
had a low-dose of prednisolone, one 
received prednisolone and hydroxy-
chloroquine and the third was treated 
with prednisolone and azathioprine. 
The clinical characteristics of the pSS 
patients have been described in detail 
previously (12).
In addition, 14 control plasma samples 
for FURIN ELISA measurements and 
10 PBMC samples for qPCR analy-
ses were collected from anonymous 
healthy blood donors (Finnish Red 
Cross Blood Transfusion Service, 
Tampere, Finland). Median age of the 
14 anonymous healthy blood donors 
(6 female, 8 male) for FURIN ELISA 
measurements was 50 years (range 
21–63 years). 
Measurement of plasma 
FURIN levels
The plasma concentration of FURIN 
was determined using a commercial 
Human FURIN Enzyme-Linked Immu-
nosorbent Assay (ELISA) Kit (Sigma-
Aldrich®, St. Louis, MO, USA) accord-
ing to the manufacturer’s instructions. 
The detection limit of the ELISA assay 
was 123 pg/ml, and concentrations be-
low this were considered to represent 
absence of the protein. Duplicate sam-
ples were analysed to ensure reliable 
results. The patients were further strati-
ÀHG LQWR ORZDQGKLJKSODVPD)85,1
groups by a median plasma FURIN 
concentration of 2690 pg/ml.
RNA isolation and qRT-PCR analysis
Total RNAs were isolated from PB 
mononuclear cells (PBMCs). The ex-
pression of FURIN (FURIN) and the 
TATA-binding protein (TBP, house-
NHHSLQJ JHQHV ZHUH TXDQWLÀHG E\
real-time PCR using the CFX instru-
ment (Bio-Rad, Hercules, CA, USA). 
Primers: 5’-GGCAAAGCGACGG-
ACTAAAC-3’ and 5’-CGTCCAGA-
ATGGAGACCACA-3’ for FURIN 
and 5´-GAATATAATCCCAAGCGGT-
TTG-3´ and 5´-ACTTCACATCACA-
GCTCCCC-3’ for TBP (12). The rela-
tive FURIN expression was calculated 
by dividing mean expression values 
of FURIN measured from triplicated 
samples by mean expression values ob-
tained for the TBP house-keeping gene.
Statistical analysis
Statistical analyses were performed with 
SPSS Statistics (IBM, v. 20). The Mann-
Whitney U-test was used for compari-
sons of continuous variables. Correla-
tions were calculated with Spearman’s 
FRUUHODWLRQ FRHIÀFLHQW )LQGLQJV ZHUH
FRQVLGHUHG VWDWLVWLFDOO\ VLJQLÀFDQW DW
p<0.05.
Ethical considerations
The study was approved by the Ethi-
cal Committee of Tampere University 
Hospital and conducted according to 
the principles of the Declaration of 
Helsinki. Written informed consent 
was obtained from all participants.
Results
First, to evaluate whether FURIN is 
elevated in pSS we measured protein 
levels in plasma using a commercial 
ELISA assay. Plasma FURIN levels 
ZHUH VLJQLÀFDQWO\ XSUHJXODWHG LQ SD-
tients with pSS compared to healthy 
controls (median 2690 pg/ml vs. 0 pg/
ml, p=0.0181, Fig. 1A). Consistent 
with the plasma data, also FURIN gene 
H[SUHVVLRQLQ3%0&VZDVVLJQLÀFDQWO\
higher among patients with pSS com-
pared to the controls (p=0.0061, Fig. 
1B). 
Next, we examined if the upregulated 
plasma FURIN associates with clinical 
or immunological features of patients 
with pSS. To this end, the pSS patients 
were divided into high and low-level 
FURIN groups with a cut-off at the 
median FURIN concentration 2690 pg/
ml (Table I). Patients with high FURIN 
FRQFHQWUDWLRQV VKRZHG VLJQLÀFDQWO\
HOHYDWHG OHYHOV RI ,)1Ƣ FRPSDUHG WR
those with low FURIN concentrations 
(median 100 pg/ml vs. 27.2 pg/ml, 
p=0.036). Moreover, they had a longer 
duration of sicca symptoms of the eyes 
(median 13 years vs. 9 years, p=0.035). 
7KHUHZDVDOVRDVWDWLVWLFDOO\VLJQLÀFDQW
correlation between plasma FURIN-
OHYHOV DQG ,)1Ƣ OHYHOV 6SHDUPDQQ
correlation, r=0.631, p=0.009) and 
with the duration of sicca symptoms 
of the eyes (r=0.520, p=0.038). In ad-
dition, there was a trend towards lower 
levels of serum beta-2 microglobulin 
in pSS patients with high FURIN lev-
els compared to those with low levels 
Fig. 1. FURIN levels in patients with primary Sjögren’s syndrome (pSS) and in healthy controls. 
The horizontal lines represent the median values within the groups.
A. Plasma FURIN levels in patients with pSS compared to healthy controls. *p=0.0181.
B. FURIN gene expression in PBMCs from patients with pSS compared to healthy controls. 
**p=0.0061.
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(median 2.30 mg/ml vs. 3.05 mg/ml, 
p=0.050). ESR (median 11 mm/h vs. 29 
mm/h, p=0.138) and the systemic dis-
ease activity index ESSDAI (median 
3.00 vs. 6.50, p=0.205) were also lower 
in pSS patients with high FURIN levels 
(Table I).
Discussion 
Previous studies have shown a connec-
tion between FURIN and various con-
GLWLRQVLQYROYLQJFKURQLFLQÁDPPDWLRQ
such as atherosclerosis (5), rheumatoid 
arthritis (8) and SLE (9). In keeping 
with these, our recent study with 537 
patients with a suspected infection indi-
cated a strong association between high 
plasma FURIN levels and a history of 
rheumatic disease (13), yet there was 
no connection between plasma FURIN 
levels and demographic features such 
as age and sex (13). In the present study, 
we show that both FURIN plasma lev-
els as well as FURIN gene expression 
DUHVLJQLÀFDQWO\KLJKHULQSDWLHQWVZLWK
pSS compared to healthy controls, im-
plying that FURIN might have a role in 
the pathology of pSS.
$ VLJQLÀFDQW DVVRFLDWLRQ ZDV IRXQG
between high plasma levels of FURIN 
and elevated plasma levels of the pro-
LQÁDPPDWRU\ F\WRNLQH ,)1Ƣ ,)1Ƣ
is generally known to mediate Th1 
cell functions, macrophage activation 
and immunoglobulin class switching, 
and it has previously been widely as-
sociated with systemic autoimmunity. 
:KDWLVQRWHZRUWK\,)1ƢDQG)85,1
mRNAs are simultaneously expressed 
by Th1 cells and they are regulated via 
the IL-12/Stat4 pathway (6). However, 
KHUHZHGHPRQVWUDWH IRU WKHÀUVW WLPH
WKDW,)1ƢDQG)85,1DOVRFRUUHODWHDW
the protein level in PB.
An association was also found between 
high FURIN plasma levels and the du-
ration of sicca symptoms of the eyes. 
,QDGGLWLRQWKHUHZDVDQRQVLJQLÀFDQW
trend showing that pSS patients with 
high plasma FURIN levels had milder 
FOLQLFDOÀQGLQJVi.e. lower serum beta-
2 microglobulin levels, ESR and ES-
SDAI. As has been previously shown, 
FURIN is essential for maintaining 
peripheral tolerance by regulating 
WKHPDWXUDWLRQRI7*)ơ$
)85,1 GHÀFLHQF\ OHDGV WR WKH GHYHO-
opment of less protective Treg cells 
and a production of overly activated 
effector T cells with no susceptibil-
ity to suppressive actions of wild-type 
Treg cells (3). A potentially protective 
role of systemic FURIN has previously 
been reported in patients with rheuma-
toid arthritis (8), where it seemed to re-
verse the Th1/Th2 balance in the joints 
and enhance the proportion of T regu-
latory (Treg) cells in the spleen. The 
protective, symptom-reducing effect of 
FURIN is additionally supported by the 
fact that active FURIN has been shown 
to restrain the production of proin-
ÁDPPDWRU\ F\WRNLQHV LQPDFURSKDJHV
(14). However, the immunoregulatory 
role of FURIN is multifaceted. While 
it seems evident that FURIN exerts an 
LPSRUWDQW DQWLLQÁDPPDWRU\ IXQFWLRQ
LW FDQ DOVR SURPRWH SURLQÁDPPDWRU\
cytokines including the central pSS cy-
tokine BAFF (5).
Elevated levels of FURIN have previ-
ously been reported in salivary glands 
of pSS patients (15). To our knowl-
HGJH WKLV LV WKH ÀUVW VWXG\ TXDQWLWDW-
ing the protein levels of FURIN in 
plasma and the expression of FURIN 
mRNA in PBMCs in patients with pSS. 
In conclusion, we demonstrate that 
both plasma FURIN levels as well as 
FURIN gene expression in PBMCs are 
higher in patients with pSS compared 
to healthy controls. In addition, a trend 
WRZDUGVVRPHZKDWPLOGHUFOLQLFDOÀQG-
ings in patients with high plasma levels 
RI )85,1 ZDV REVHUYHG 7KHVH ÀQG-
ings are consistent with previous stud-
LHVRQRWKHULQÁDPPDWRU\GLVHDVHVDQG
PLJKW UHÁHFW D SRWHQWLDOO\ SURWHFWLYH
role of FURIN in patients with pSS by 
preventing the autoimmune responses 
and overly activated immune system 
Table I.&OLQLFDODQGLPPXQRORJLFDOÀQGLQJVLQSDWLHQWVZLWKS66JURXSHGE\PHGLDQ
plasma FURIN concentrations.
 Plasma FURIN concentration 
9DULDEOH SJPO SJPO p-value 
 n=8 n=8
Age, years 52 (40-64) 57 (43-75) 0.563
Duration of sicca symptoms of the eyes, years 7 (3-15) 19 (14-35) 0.035
Duration of sicca symptoms of the mouth, years 10 (6-22) 15 (10-21) 0.461
Disease duration, years 9 (5-17) 13 (6-19) 0.599
ESSPRI, cm  4.37 (3.17-6.33) 4.28 (2.15-5.76) 0.674
ESSDAI 6.50 (4.25-9.75) 3.00 (2.25-7.50) 0.205
Pain-VAS, cm 4.0 (0-66.0) 5.5 (0-16.0) 0.675
PGH-VAS, cm 15.0 (1.0-71.0) 14.5 (2.25-25.0) 0.523
HAQ 0.00 (0-0.38) 0.13 (0-1.10) 0.433
Haemoglobin, g/L 130 (121-136) 137 (126-142) 0.247
ESR, mm/h 29 (11-37) 11 (8-19) 0.138
C-reactive protein, g/L 0.85 (0-2.55) 0.00 (0.00-0.75) 0.277
Serum IgG, g/L 17.8 (16.5-22.3) 16.9 (14.3-20.8) 0.462
Serum IgA, g/L 2.63 (1.78-3.15) 2.12 (0.25-3.15) 0.400
Serum IgM, g/L 1.50 (0.92-2.97) 1.14 (0.61-2.21) 0.600
6HUXPơPPJ/     
Serum C3, g/L 0.98 (0.84-1.21) 0.98 (0.83-1.15) 1.000
Serum C4, g/L 0.16 (0.11-0.17) 0.14 (0.12-0.18) 0.792
Anti-SSA antibody titre 240 (240-240), n=7 240 (240-240), n=6 1.00
Anti-SSB antibody titre 320 (72-320), n=7 183 (0-320), n=6 0.174 
Plasma IL-1 beta, pg/mL 13.9 (1.93-33.6) 18.8 (6.14-24.6) 0.674
Plasma IL-2, pg/mL 21.5 (9.23-112) 67.0 (21.1-108) 0.345
Plasma IL-4, pg/mL 53.1 (42.6-96.7), n=7 146.3 (37.8-347), n=7 0.406 
Plasma IL-6, pg/mL 8.04 (4.06-21.4), n=7 13.7 (7.65-31.0) 0.487
Plasma IL-7, pg/mL 15.2 (5.46-21.7) 22.5 (17.4-45.3) 0.115 
Plasma IL-10, pg/mL 74.1 (33.7-258) 110.5 (59.0-360) 0.418
3ODVPD,)1ƢSJP/     
3ODVPD71)ƠSJP/     
Statistical analysis: Mann Whitney test. The values are expressed as medians (interquartile range). 
ESSPRI: EULAR Sjögren’s syndrome patient-reported index; ESSDAI: EULAR Sjögren’s syndrome 
disease activity index; VAS: visual analogue scale; PGH: patient’s global health assessment; HAQ: 
Health Assessment Questionnaire; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; 
ơPEHWDPLFURJOREXOLQ,/LQWHUOHXNLQ,)1LQWHUIHURQ71)WXPRXUQHFURVLVIDFWRU
S-50 Clinical and Experimental Rheumatology 2018
FURIN and Sjögren’s syndrome / N. Ranta et al.
RUFKHVWUDWHGE\,)1Ƣ,QH[SHULPHQWDO
models, exogenous FURIN has been 
successfully used to harness autoim-
munity (8). Taking into account the 
clinical diversity of pSS, it would be 
important to analyse FURIN levels in 
subgroups of pSS patients with vari-
ous extraglandular symptoms and in 
SDWLHQWVFODVVLÀHGE\GLVHDVHGXUDWLRQ
Therefore, further studies with more 
S66 SDWLHQWV DUH QHHGHG WR FRQÀUP
WKH FXUUHQW ÀQGLQJV DQG WR UHÀQH RXU
knowledge of the possible clinical fea-
sibility of targeting FURIN in pSS. 
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rheumatoid arthritis
A Valli1*, N Ranta1,2*, A Grönholm1,2, O Silvennoinen1,3, M Pesu1,2,4**, P Isomäki1,5**
1Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland
2BioMediTech, Tampere, Finland
3Fimlab Laboratories, Tampere, Finland
4Department of Dermatology, Tampere University Hospital, Tampere, Finland
5Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland
Objective: FURIN is a proprotein convertase enzyme that inhibits the proinﬂammatory function of T cells and
myeloid cells. Elevated FURIN expression levels have been reported in immune-mediated diseases, such as primary
Sjögren’s syndrome. Here, we investigated the levels of FURIN in peripheral blood (PB) and synovial ﬂuid (SF)
leucocytes from patients with rheumatoid arthritis (RA).
Method: FURIN mRNA expression in PB and SF cells was determined by quantitative reverse transcription–
polymerase chain reaction and FURIN plasma levels were measured using enzyme-linked immunosorbent assay.
Associations between FURIN levels and demographic and clinical characteristics of the patients were determined.
Results: FURIN levels were signiﬁcantly elevated in PB and SF mononuclear cells, T cells, and monocytes from RA
patients compared to healthy controls. High FURIN levels were signiﬁcantly associated with the prevailing predni-
solone treatment, higher prednisolone doses, and increased C-reactive protein levels and Health Assessment Ques-
tionnaire values.
Conclusion: FURIN is signiﬁcantly upregulated in RA PB and SF leucocytes, suggesting that it may have a role in the
pathogenesis of RA. In addition, our results suggest that elevated FURIN expression is associated with the indicators
of more severe RA.
In rheumatoid arthritis (RA), T cells, B cells, macrophages,
and dendritic cells accumulate in the joints. Different cell
types promote inﬂammation by secreting proinﬂammatory
cytokines, such as tumour necrosis factor-α (TNF-α), inter-
feron-γ (IFN-γ), granulocyte–macrophage colony-stimulat-
ing factor (GM-CSF), interleukin-1 (IL-1), IL-6, and IL-17
(1). These events ultimately lead to chronic inﬂammation,
synovial hyperplasia and degradation of articular cartilage
and bone (2).
FURIN was the ﬁrst mammalian proprotein convertase
(PCSK) enzyme to be discovered. FURIN belongs to the
subtilisin superfamily of serine endoproteases and it con-
verts immature proproteins into functional units (3).
FURIN is essential formammalian development and tissue
homeostasis, but also contributes to the pathogenesis of
several diseases, including cancers, elevated blood pres-
sure, and atherosclerosis (4–6).
FURIN is important in the regulation of the immune
system. Deleting FURIN in mouse T cells results in a
loss of peripheral immune tolerance and aberrant
T-helper cell polarization (7). In the myeloid cells,
FURIN inhibits inﬂammatory responses by reducing
the production of proinﬂammatory cytokines (8). The
function of FURIN in immunoregulation is not entirely
clear, but its expression in immune cells is critical for
the functional maturation of anti-inﬂammatory pro-
transforming growth factor-β1 (pro-TGF-β1) cytokine
and the suppressive function of regulatory T cells (7).
Preliminary evidence also suggests that FURIN plays a
role in the pathogenesis of human autoimmune diseases.
In primary Sjögren’s syndrome, an upregulated expression
of FURIN has been detected in salivary gland biopsies (9)
and in peripheral circulation (10). Previously, we found an
association between a high plasma level of FURIN and a
history of rheumatic disease in a prospective cohort study
of patients with a suspected infection in the emergency
room (11). We have therefore investigated FURIN levels
in peripheral blood (PB) and synovial ﬂuid (SF) leuco-
cytes from RA patients. We also explored possible
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associations between FURIN levels and demographic and
clinical characteristics of the patients.
Method
Patient samples
PB and SF samples were collected from patients with
active RA. The characteristics of the patient cohorts are
presented in Tables 1 and 2. In addition, puriﬁed T cells
and monocytes were obtained from eight RA patients,
with a median (range) age of 62 (37–87) years, duration
of disease 18.5 (0.25–49) years, C-reactive protein
(CRP) 25 (18–67.4) g/L, and erythrocyte sedimentation
rate (ESR) 35.5 (10–91) mm/h. Control samples were
obtained from healthy blood donors (Finnish Red Cross
Blood Transfusion Service, Tampere).
All patients gave their written informed consent. This
study was approved by the Ethical Committee of Tampere
University Hospital, Tampere, Finland, and conducted
according to the principles of the Declaration of Helsinki.
Cell preparations
Peripheral blood mononuclear cells (PBMCs) and synovial
ﬂuid mononuclear cells (SFMCs) were isolated by Ficoll-
Paque Plus (Amersham Biosciences, Amersham, UK)
density gradient centrifugation. T cells and monocytes
were further puriﬁed from eight RA patients usingmagnetic
beads (Miltenyi Biotec, Auburn, CA, USA). T cells were
puriﬁed by negative selection (Pan T Cell Isolation Kit;
Miltenyi Biotec) and monocytes were isolated by positive
selection using anti-CD14-coated microbeads.
RNA isolation and quantitative reverse transcription–
polymerase chain reaction (qRT-PCR) analysis
Total RNA was isolated using the RNeasy MiniKit (Qia-
gen, Valencia, CA, USA). Total RNA was reverse tran-
scribed using Maxima Reverse Transcriptase (Thermo
Scientiﬁc, Waltham, MA, USA) and random hexamers
(Thermo Scientiﬁc). The real-time PCR was carried out
with the CFX96 instrument (Bio-Rad, Hercules, CA,
USA) using a Maxima SYBR Green/ROX master mix
(Thermo Scientiﬁc).
The following primers for FURIN and TATA-binding
protein (TBP, housekeeping) were used: 5′-GAATA-
TAATCCCAAGCGGTTTG-3′ and 5′-ACTTCACATCA
CAGCTCCCC-3ʹ for TBP and 5ʹ-GGCAAAGCGACG-
GACTAAAC-3ʹ and 5ʹ-CGTCCAGAATGGAGACCA
CA-3ʹ for FURIN.
Mean FURIN expression values from triplicate sam-
ples were obtained by dividing them by the mean values
obtained for the TBP housekeeping gene.
Table 1. Associations of patients’ characteristics and clinical parameters with FURIN mRNA levels in peripheral blood mono-
nuclear cells (PBMCs) and synovial ﬂuid mononuclear cells (SFMCs).
FURIN mRNA in PBMCs FURIN mRNA in SFMCs
n = 16 r p n = 8 r p
Characteristics
Age* (years) 66 (32–88) 0.0074 0.9784 54 (32–72) −0.0238 0.9554
Gender (male) 7 (44) 0.7577 6 (75) 0.8571
Duration of disease (years) 15 (0–37) −0.0517 0.8493 11 (1–37) −0.4762 0.2329
Clinical parameters
CRP (g/L) 30 (11–114) 0.3944 0.1306 44 (15–114) 0.9523 0.0003
ESR (mm/h) 42 (10–118) 0.0383 0.8881 32 (10–88) 0.6667 0.0710
SJC 7 (1–16) 0.3208 0.2258 7 (1–9) 0.3879 0.3423
TJC 6 (0–16) 0.2316 0.3880 3 (1–9) −0.1473 0.7278
DAS28 (ESR) 5.3 (3.0–6.3) 0.2235 0.4053 4.8 (3.0–5.6) 0.4192 0.3013
VAS, global health 56 (0–100) 0.4341 0.0929 47 (1–90) 0.5714 0.1390
VAS, pain 58 (0–100) 0.3765 0.1506 47 (2–92) 0.5714 0.1390
HAQ 1.51 (0.00–2.50) 0.1550 0.5666 1.19 (0.00–1.74) −0.2892 0.4873
RF positivity 10 (63) 0.1471 3 (38) 0.1429
Current treatment
Prednisolone 12 (75) 0.0198 6 (75) 0.4286
Prednisolone dose (mg) 6.3 (0.0–15.0) 0.6809 0.0037 8.8 (0.0–25.0) 0.6747 0.0664
Methotrexate 7 (44) 0.6065 4 (50) 0.3429
DMARD 15 (94) 0.2500 7 (88) 1.0000
Biologics 2 (13) 0.2667 4 (50) 0.8857
Data are reported as median (range) or number (percentage).
The expression of FURIN mRNA was calculated in relation to the TATA-binding protein (TBP) expression (FURIN/TBP).
*Age at the time of sampling.
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; SJC, swollen joint count; TJC, tender joint count; DAS28, 28-joint
Disease Activity Score; VAS, visual analogue scale; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; DMARD,
disease-modifying anti-rheumatic drug.
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FURIN enzyme-linked immunosorbent assay (ELISA)
FURIN plasma levels were measured using the Human
Furin ELISA kit (Thermo Scientiﬁc). Duplicate determina-
tions were carried out for each sample. The analysis was
performedwith a cut-off by dividing samples into those that
were below the detection threshold (< 123 pg/mL) and
those at or above it (≥ 123 pg/mL).
Statistical analysis
Statistical analyses were performed using SPSS Statistics
version 22 (IBMCorp., Armonk, NY, USA). Fisher’s exact
test was used to test the relationship between two binomial
variables. Analyses including ordinal and scale variables
were conducted using the Mann–Whitney U-test (exact).
The correlations for continuous variables were calculated
using Spearman’s correlation coefﬁcient.
Results
Increased expression of FURIN in PB and SF T cells and
monocytes from RA patients
First, we examined the levels of FURIN mRNA in
PBMCs from patients with active RA and healthy con-
trols. The expression of FURIN was signiﬁcantly
elevated in PBMCs from RA patients compared with
healthy controls (p < 0.001) (Figure 1A).
To gain better insight into the cell populations which
expressed increased levels of FURIN, we studied the
expression of FURIN mRNA in isolated PB T cells and
monocytes. As shown in Figure 1B and C, the levels of
FURIN were elevated in both PB T cells and monocytes
fromRA patients compared to healthy controls, with mono-
cytes expressing higher levels of FURIN than T cells.
In RA, SF T cells and macrophages are exposed to
various inﬂammatory stimuli, and show an activated phe-
notype compared to the cells in PB. To investigate whether
the cells from the inﬂamed joints express even higher levels
of FURIN, SFMCs, SF T cells, and SF monocytes were
isolated from patients with active RApresentingwith arthri-
tis of the knee joint. The levels of FURIN mRNA in
SFMCs, T cells, and monocytes were comparable to those
in RA PB cells (Figure 1A–C).
Finally, we also evaluated FURIN plasma levels in
patients with RA and healthy controls. Plasma FURIN
levels in both healthy controls and patients with RA varied
considerably and no signiﬁcant difference was observed
between RA patients and healthy controls (p = 0.23) (Fig-
Figure 1D). However, more patients (10 out of 17, 59%)
than controls (ﬁve out of 14, 35%) demonstrated detectable
levels of FURIN (≥ 123 pg/mL).
Table 2. Patients’ characteristics and clinical parameters in all plasma samples and in two groups showing FURIN plasma levels
below or above the detection threshold of the FURIN enzyme-linked immunosorbent assay (ELISA).
All samples
(n = 17)
FURIN < 123 pg/mL
(n = 7)
FURIN ≥ 123 pg/mL
(n = 10) p
Characteristics
Age* (years) 66 (52–88) 66 (58–77) 68 (52–88) 0.9056
Gender (male) 4 (24) 1 (14) 3 (30) 0.6029
Duration of disease (years) 7 (0–29) 7 (0–26) 8.5 (0–29) 0.9619
Clinical parameters
CRP (g/L) 18 (0–68) 16 (0–39) 20 (0–68) 0.3772
ESR (mm/h) 40 (7–118) 40 (7–80) 41 (8–118) 0.5843
SJC 8 (1–15) 7 (1–9) 8 (4–15) 0.1633
TJC 6 (0–37) 6 (3–25) 5.5 (0–37) 0.9423
DAS28 (ESR) 5.6 (3.5–6.9) 5.5 (3.7–5.9) 5.7 (3.5–6.9) 0.2698
VAS, global health 63 (0–93) 56 (0–85) 72 (5–93) 0.3638
VAS, pain 55 (0–100) 54 (0–88) 64 (6–100) 0.5537
HAQ 1.25 (0.63–2.75) 0.75 (0.63–1.63) 1.74 (0.75–2.75) 0.0031
RF positivity 10 (59) 3 (43) 7 (70) 0.3500
Current treatment
Prednisolone 13 (77) 4 (57) 9 (90) 0.2500
Prednisolone dose (mg) 7.5 (0.0–27.5) 5 (0.0–7.5) 10 (0.0–27.5) 0.0234
Methotrexate 8 (47) 3 (43) 5 (50) 1.0000
DMARD 12 (71) 5 (71) 7 (70) 1.0000
Biologics 4 (24) 1 (14) 3 (30) 0.6029
Data are reported as median (range) or number (percentage).
The p-values were derived from comparisons of the groups showing FURIN levels below or above the detection threshold of the
FURIN ELISA.
*Age at the time of sampling.
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; SJC, swollen joint count; TJC, tender joint count; DAS28, 28-joint
Disease Activity Score; VAS, visual analogue scale; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; DMARD,
disease-modifying anti-rheumatic drug.
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Correlation of FURIN levels with clinical characteristics
of RA patients
We next examined whether FURIN mRNA levels in
PBMCs or SFMCs correlated with any of the demo-
graphic or clinical characteristics of RA patients. We
found a signiﬁcant correlation between current predni-
solone use (p = 0.020) and dose (p = 0.004) and FURIN
mRNA levels in PBMCs. The expression of FURIN in
SFMCs, in turn, showed a very strong correlation with
the CRP level (p < 0.001) (Table 1). In addition, there
were trends towards associations between FURIN level
in SFMCs and ESR (r = 0.6667, p = 0.0710) and
prednisolone dose (r = 0.6747, p = 0.0664).
We also examined whether FURIN levels in plasma
were associated with any of the clinical characteristics.
The Health Assessment Questionnaire (HAQ) disability
index (p = 0.003) and prednisolone dose (p = 0.023) were
signiﬁcantly higher in the group demonstrating detectable
levels of FURIN (Table 2). In addition, IL-1β, IL-2, IL-4,
IL-6, IL-7, IL-10, IFN-γ, and TNF-α levels in plasma were
determined in 10 patients and their levels were correlated
with those of FURIN. The median levels of all cytokines
studied were higher in the group demonstrating detectable
levels of FURIN (n = 7) than in patients presenting with
undetectable FURIN levels (n = 3; data not shown). How-
ever, this difference was signiﬁcant only in the case of IL-2
(median 28 pg/mL vs 6 pg/mL, p = 0.033).
Discussion
The expression of FURIN in RA has not previously been
systematically studied, and no data are available regarding
FURIN expression in leucocytes from RA patients. Lin
et al (12) reported upregulated expression of FURIN in
synovial pannus derived from three patients with RA.
In addition to RA, FURIN has been found to be upregu-
lated in PBMCs and salivary gland biopsies in primary
Sjögren’s syndrome (9, 10). Elevated FURIN levels have
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Figure 1. (A–C) FURIN mRNA expression and (D) FURIN plasma levels in patients with rheumatoid arthritis (RA) and healthy controls. Levels of
FURIN mRNA were analysed by quantitative reverse transcription–polymerase chain reaction in: (A) peripheral blood (PB) mononuclear cells
(n = 16) and synovial ﬂuid (SF) mononuclear cells (n = 8); (B) T cells (n = 7 for PB and n = 4 for SF); and (C) monocytes (n = 6 for PB and n = 4
for SF) from healthy controls and patients with RA. Paired PB/SF samples were available from three patients in the mononuclear cell analysis, from
four patients in the T-cell analysis, and from three patients in the monocyte analysis. Data are presented as relative FURIN expression divided by
TATA-binding protein (TBP) level (A–C). (D) FURIN protein levels were measured by enzyme-linked immunosorbent assay in plasma samples
from healthy controls and RA patients. Horizontal lines indicate the mean expression levels in each group. The detection limit of the assay was
123 pg/mL. Signiﬁcant differences between study groups are marked with asterisks: *p < 0.05, **p < 0.01, ***p < 0.001.
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also been seen in patients with systemic lupus erythema-
tosus (13). Together, these previous results and our current
ﬁndings showing increased FURIN expression in RA
indicate that FURIN is upregulated in different types of
rheumatic disease.
Our results show that FURIN levels are associated with
prednisolone treatment and dose, CRP levels, ESR, and
HAQ disability index. Since prednisolone is used in the
treatment of active RA, these ﬁndings suggest that FURIN
is elevatedmostly in patients with active and severe disease.
This conclusion is supported by the fact that patients with
elevated FURIN levels also showed global upregulation of
plasma cytokines, particularly IL-2 associated with T-cell
activation. These ﬁndings are also in line with our previous
results indicating that FURIN expression is upregulated
upon the activation of T cells and macrophages (5, 7).
However, the inﬂammatory response in RA joints per se
does not seem to result in further FURIN upregulation,
since comparable levels of FURIN were observed in PB
and SF samples.
Previous results suggest that FURIN has chieﬂy a protec-
tive role in arthritis. Systemic administration of FURINwas
shown to ameliorate collagen-induced arthritis in mice (12).
In addition, inhibition of FURIN was shown to enhance the
invasive phenotype of synoviocytes from patients with RA
(14). The protective role of FURIN in autoimmunity is also
supported by previous results showing that FURIN is essen-
tial in maintaining peripheral immune tolerance (7) and that
it inhibits proinﬂammatory cytokine production in myeloid
cells (8). Notably, FURIN has been reported to inhibit
matrix metalloproteinase-13 and to limit osteoarthritis in
mice (15). The idea of using FURIN, its biologically active
derivatives, or its inhibitors in the treatment of inﬂammatory
diseases has been documented in patent applications
(US20040127396A1 and WO2011144517A1).
Our current results suggesting that FURIN expression
is associated with more active and severe RA are in line
with previous data showing the upregulation of the anti-
inﬂammatory cytokines IL-10 and TGF-β (1) in RA
patients. The overexpression of these regulatory pro-
teins may reﬂect an attempt to combat inﬂammation,
but owing to the plethora of proinﬂammatory mediators
present in RA, inﬂammation persists despite the actions
of FURIN and other immunosuppressive proteins.
Conclusion
Taken together, our data demonstrate that FURIN is upre-
gulated in severe RA. Further investigations are warranted
to better determine the role of FURIN in the pathogenesis of
RA and its potential value as a biomarker in inﬂammatory
diseases.
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